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Abstract
Paclitaxel is effective against a wide range of cancers which are considered to be 
refractory to conventional therapy. It is hydrophobic and thus its solubility in an aqueous 
medium is poor. Therefore, several approaches have been investigated to enhance the 
therapeutic potential of paclitaxel in order to overcome the associated problems. Cisplatin has 
been broadly used anticancer agent for treatment of various types of cancer. However, the 
efficacy of this chemotherapeutic drug is weak by drug resistance in the advanced stage of the 
cancer. On the other hand, cisplatin in combination with other agents would be useful for 
effective treatment of cancer. Curcumin is the yellow pigment found in the Indian spice curry 
and extensively used in human diet. It has broad biological and pharmacological fonctions, 
and it is a candidate to design potential therapeutic strategies for treatment of cancer. In the 
present study, novel drug delivery formulations were designed in order to enhance therapeutic 
activity of well-known chemotherapic molecules paclitaxel, cisplatin and curcumin. Further, 
combination effect curcumin with toxic anticancer molecules paclitaxel and cisplatin was also 
investigated.
Firstly, the novel L-glutamic acid derivative of p-cyclodextrin (CD-Glu) was 
designed and paclitaxel complex of CD-Glu was investigated to improve its water-solubility, 
stability and bioactivity for therapeutic applications. The new paclitaxel/CD-Glu 
complexation was tested on four cancer models; ovarian, lung, prostate and breast cancers. 
Cell viability, Annexin V apoptotic and colony formation assays showed that CD-Glu 
encapsulation significantly enhances the cytotoxicity of paclitaxel.
Secondly, a novel drug nano-carrier system was formulated by encapsulating 
curcumin and paclitaxel in poly(P-cyclodextrintriazine) (PCDT) for the therapy of four cancer 
models; ovarian, lung, prostate and breast cancers. Cell viability, colony formation and 
Annexin V apoptotic studies revealed improved curcumin cytotoxicity upon complexation.
Moreover, a synergism was found between curcumin and paclitaxel, particularly when 
complexed with PCDT on A2780, SKOV-3 and H1299 cancer cell lines.
Finally, a novel oleic acid coupled poloxamer (POA) hydrogel is synthesized to 
enhance chemotherapeutic effects of curcumin and cisplatin. Cell viability, colony formation 
and Annexin V apoptosis assays revealed that amphiphilic and thermosensitive POA hydrogel 
robustly augments the cytotoxicity of cisplatin in three cancer models; ovarian, lung and 
prostate cancer. In addition, a synergism was determined between cisplatin and curcumin, in 
particular when formulated with POA hydrogel on A2780 and HI299 cell lines.
II
This thesis and the work to which it refers are the results o f my own efforts. Any ideas, 
data, images or text resulting from the work o f others (whether published or 
unpublished) are fully identified as such within the work and attributed to their 
originator in the text, bibliography or in footnotes. This thesis has not been submitted 
in whole or in part for any other academic degree or professional qualification. I  
agree that the University has the right to submit my work to the plagiarism detection 
service TurnitinUK for originality checks. Whether or not drafts have been so- 
assessed, the University reserves the right to require an electronic version o f the final 
document (as submitted) for assessment as above.
Signature of Candidate Date
III
TABLE OF CONTENTS
ABSTRACT I
DISCLAIMER " III
TABLE OF CONTENTS IV
LIST OF FIGURES VII
LIST OF TABLES XII
Chapter 1
Introduction 1
1.1. Paclitaxel 2
1.1.1. Chemistry of paclitaxel 3
1.1.2. Physical properties and pharmacokinetics of 4 
paclitaxel
1.1.3. Solubility of paclitaxel 5
1.1.4. Mechanism of action of paclitaxel 6
1.1.5. Paclitaxel dosage forms and problems 7
1.1.6. Paclitaxel delivery 9
1.2. Curcumin 10
1.2.1. History of curcumin 11
1.2.2. Chemistry of curcumin 12
1.2.3. Therapeutic potential of curcumin 14
1.2.4. Therapeutic limitations of curcumin 16
1.3. Cisplatin 16
1.3.1. History of cisplatin 17
IV
1.3.2. Mechanism of action of cisplatin 18
1.3.3. Therapeutic limitations of cisplatin 19
1.3.4. Combination therapy of cisplatin 19
1.4. Cyclodextrins 20
1.4.1. Cyclodextrin polymers 23
1.4.2. Inclusion properties of CDs 25
1.4.3 Complexation techniques 26
1.5. Hydrogels 28
1.5.1. Introduction to hydrogels 2 8
1.5.2. Thermo-responsive hydrogels for pharmaceutical 
applications 30
1.6. Aim and Objectives 34
1.7. References 35
Chapter 2
Enhancement of Bioactivity of Paclitaxel by p-CycIodextrin-
L-Glutamic Acid Encapsulation 49
2.1. Abstract 50
2.2. Introduction 51
2.3. Materials and methods 53
2.4. Results and Discussion 58
2.5. References 69
Chapter 3
Synergistic Interaction of Paclitaxel and Curcumin with
Cyclodextrin Polymer Complexation in Human Cancer Cells 72
V
3.1. Abstract 73
3.2. Introduction 75
3.3. Materials and methods 78
3.4. Results 84
3.5. Discussion 97
3.6. References 101
Chapter 4
Conjoint Antitumor Effects of Cisplatin and Curcumin in
Oleic Acid Coupled Poloxamer Formulation 106
4.1. Abstract 107
4.2. Introduction 108
4.3. Materials and methods 111
4.4. Results 115
4.5. Discussion 127
4.6. References 131
Chapter 5
Conclusions and Future Directions 137
Abbreviations 143
Definitions 146
V I
List of Figures
Chapter 1
Figure 1.1. Structure of paclitaxel. 4
Figure 1.2. Mechanism of action of paclitaxel. 7
Figure 1.3. Alternative approaches for paclitaxel formulation. 10
Figure 1.4. Structure of three major curcuminoids in turmeric. 12
Figure 1.5. Structure of curcumin in keto and enol forms. 13
Figure 1.6. The chemical structures of cisplatin in 2D and 3D. 16
Figure 1.7. (3-Cyclodextrin: structure of P-cyclodextrin (a), functional 22
scheme of the cyclodextrin (b) p-Cyclodextrin is the most commonly 
used cyclodextrin because of its appropriate cavity size and due to the 
lowest price.
Figure 1.8. Water molecules in the cavity of P-CD. It is obtained by 23
Spartan-Computer modeling. There is space for 11 water molecules in the 
cavity of p-CD.
Figure 1.9. Scheme of the main types of CD polymers. 24
Figure 1.10. The transition diagrams of copolymers in water that display 31
(A) sol-gel-sol transitions (class 1), and (B) gel-sol transitions (class 2).
Figure 1.11. Molecular structure of hydrogel forming polymers or copolymer 32 
building blocks.
Chapter 2
Figure 2.1. Structure of paclitaxel. 51
Figure 2.2. NMR spectrum of p-cyclodextrin triazine (A), L-Glutamic 59
acid monosodium salt (B) and glutamic acid derivative of P-cyclodextrin
V II
(CD-Glu) (C).
Figure 2.3. Phase solubility diagram of paclitaxel/CD-Glu complexes. 60
Figure 2.4. Cytotoxic effect of paclitaxel alone and complexed with CD-Glu 62
on A2780, SKOV-3, HI299, DU-145 and MCF-7 cell lines as assessed by 
the MTT method for 72 h. CD-Glu complexes of paclitaxel have an improved 
therapeutic effect on all cancer cell lines compared to tree paclitaxel. Values 
are means (n =3) ±SD.
Figure 2.5. The IC50 values (50% of cell growth inhibition) of paclitaxel 63
and paclitaxel/CD-Glu on MCF-7, DU-145, SKOV-3, A2780 and HI299 
cell lines.
Figure 2.6. (A) Representative images of colony forming assays 65
paclitaxel (Pax) and paclitaxeFCD-Glu complexes. Cells (500) were
seeded in culture dishes and after 24 h treated with the indicated amounts
of paclitaxel or paclitaxel/CD-Glu. Cells were allowed to grow for 11
days. (B) Colony densities were expressed as a per cent of the control
cells. The results show the mean± SE values.
Figure 2.7. CD-Glu complexation of paclitaxel mostly increases the 6 6
number of apoptotic cells. Four different human cancer cells (A2780,
SKOV-3, HI299 and DU-145) were treated with CD-Glu, paclitaxel and 
paclitaxel/CD-Glu complexes for 48 h. Apoptotic cells were measured 
with PE Annexin V staining by using flow cytometry.
Figure 2.8. Average cell death was determined with 7-AAD staining by 6 8
using flow cytometry. Four different human cancer cells (A2780, SKOV-3,
HI299 and DU-145) were treated with CD-Glu, paclitaxel and paclitaxel/
CD-Glu complexes for 48 h. Apoptotic cells were measured with PE 
Annexin V staining by using flow cytometry. CD-Glu complexation of 
paclitaxel mostly increases the number of dead cells.
V III
Chapter 3
Figure 3.1. Structure of Poly(P-cyclodextrin-triazine) (PCDT). 85
Figure 3.2. FT-IR spectra of p-cyclodextrin triazine (CD-TRI) and 85
poly(P-cyclodextrin triazine) (PCDT) (KBr tablet) from 4000 to 400 cm"\
Figure 3.3. ^H-NMR spectra of P-cyclodextrin triazine (CD-TRI), 86
and poly(p-cyclodextrin triazine) (PCDT) in d-DMSO.
Figure 3.4. Phase solubility diagram of curcumin-PCDT and 87
paclitaxel-PCDT complexes.
Figure 3.5. Cytotoxic effect of curcumin alone and complexed with 88
PCDT on A2780, SKOV-3, HI299, DU-145 and MCF-7 cell lines 
as assessed by the MTT method for 72 h. PCDT complexes of 
curcumin have an improved therapeutic effect on all cancer cell lines 
compared to free curcumin. Values are means (n =3) ±SD.
Figure 3.6. Cytotoxic effect of paclitaxel alone and complexed 89
with PCDT on A2780, SKOV-3, H1299, DU-145 and MCF-7 
cell lines as assessed by the MTT method for 72 h. Values are means 
(n=3)±SD.
Figure 3.7. Cytotoxic effect of free paclitaxel and free curcumin 90
combined with paclitaxel/PCDT and curcumin/PCDT in combination 
on A2780, SKOV-3, H1299, DU-145 and MCF-7 cell lines as assessed 
by the MTT method for 72 h. PCDT complexes of paclitaxel + curcumin 
have an improved therapeutic effect especially on ovarian cancer cell lines 
(A2780 and SKOV-3) compared to free paclitaxel + curcumin. Values are 
means (n =3) ±SD.
Figure 3.8. (A) Representative images of colony forming assays curcumin 95
IX
(Cur) and curcumin/PCDT complexes. (C) Representative images of colony 
forming assays paclitaxel (Pax) and paclitaxel/PCDT complexes. Cells (500) 
were seeded in culture dishes and after 24 h treated with the indicated amounts 
of curcumin or curcumin/PCDT. Cells were allowed to grow for 11 days. (B),
(D) Colony densities were expressed as a percent of the control cells. The 
results show the mean± SE values.
Figure 3.9. PCDT complexation mostly increases the number of apoptotic 96
and dead cells. Four different human cancer cells (A2780, SKOV-3, H1299 
and DU-145) were treated with curcumin (Cur) and paclitaxel (Pax) alone 
or in combination which are formulated in solution and PCDT encapsulation 
for 48 h. Apoptotic cells were measured with PE Annexin V staining and 
cell death was determined with 7-AAD staining by using flow cytometry.
Chapter 4
Figure 4.1. (A) Synthesis of POA by the reaction of oleic acid and poloxamer. 116
(B) NMR spectrum of POA in CDCI3.
Figure 4.2. Solubility of CUR in POA hydrogel. 117
Figure 4.3. Comparison of cytotoxic effect of free CPT and free CUR with 119
their POA hydrogel formulations on A2780, HI299 and DU-145 cell lines as 
assessed by the MTT method for 72 h. POA40 and POA80 means 40 pM and 
80 pM concentration of POA, respectively. POA hydrogel formulation of CPT 
has an improved therapeutic effect on all cancer cell lines compared to CPT 
alone. On the other hand, POA raises cytotoxic effect of CUR especially on 
A2780 and DU-145 cell lines. Values are means (n =3) ±SD.
Figure 4.4 Cooperative cytotoxic effect of free CPT and free CUR was 120 
compared with CPT/POA and CUR/POA in combination on A2780, HI299 
and DU-145 cell lines as assessed by the MTT method for 72 h. POA40 and
X
POA80 means 40 pM and 80 pM of POA, respectively. POA hydrogel 
formulation of CPT + CUR has an improved therapeutic effect especially 
on all three cancer cell lines compared to free CPT + CUR. Values are 
means (n =3) ±SD.
Figure 4.5. (A) Representative images of colony forming assays free CPT 124
and CPT in POA hydrogel. (C) Representative images of colony forming 
assays CUR and CUR in POA hydrogel. Cells (500) were seeded in 
culture dishes and after 24 h treated with the indicated amounts of amounts 
of anticancer agents. Cells were allowed to grow for 11 days. (B), (D)
Colony densities were expressed as a percent of the control cells at A2780 
and HI299 cell lines. The results show the mean± SE values, (p < 0.05, 
compared to the same CPT or CUR dose).
Figure 4.6. POA hydrogel mostly increases the number of apoptotic cells. 126
Human ovarian cancer cell line A2780 (A) and human nonsmall cell lung 
carcinoma cell line HI299 (B) were treated with CPT and CUR alone or in 
combination which are formulated in solution and POA formulation for 48 h. 
Apoptotic cells were measured with PE Annexin V staining by using flow 
cytometry.
Figure 4.7. Cell death was determined with 7-AAD staining. A2780 and 127
HI299 cancer cell lines were treated with CPT and CUR alone or in 
combination which are formulated in solution and POA formulation for 48 h.
Chapter 5
Figure 5.1. Representation of complexation of paclitaxel with L-glutamic 138
acid derivative of (3-cyclodextrin (Chapter 2).
Figure 5.2. Representation of complexation of curcumin and paclitaxel 139
X I
with Poly(|3-cyclodextrin-triazine) (PCDT) monomer (Chapter 3).
Figure 5.3. Structures of cisplatin, curcumin and oleic acid coupled 140
poloxamer (POA) (Chapter 4).
List of Tables
Chapter 1
Table 1.1. Summary of therapeutic efficacy and toxicities. 8
Table 1.2. General features of CDs. 21
Table 1.3. The most common hydrogel monomers for pharmaceutical 29
applications.
Chapter 3
Table 3.1. The IC50 values (50% of cell growth inhibition) of paclitaxel, 91
curcumin, paclitaxel/PCDT and curcumin/PCDT alone and in combination 
on MCF-7, DU-145, SKOV-3, A2780 and H1299 cell lines.
Table 3.2. Paclitaxel and curcumin combination index (Cl) against A2780, 92
SKOV-3, H1299, DU-145 and MCF-7 cell lines.
Chapter 4
Table 4.1. The IC50 values (50% of cell growth inhibition) of CPT, CUR, 122
CPT/POA and CUR/POA alone and in combination on A2780, HI299 and 
DU-145 cell lines.
Table 4.2. Combination index (Cl) of CPT and CUR against A2780, H1299 123
and DU-145 cell lines.
Chapter 5
X II
Table 5.1. CI values for A2780, SKOV-3, H1299, DU-145 and 141
MCF-7 cell lines.
X III
Chapter 1
Introduction
Cancer is a general word for some types of diseases initiated by unusual and 
unrestricted growth of cells. It has high morbidity and death, being the second most 
common cause o f all deaths, after cardiovascular diseases. The main objective of 
cancer treatment is to kill the cancer cells without affecting the normal tissue. The 
main method to achieve this is by triggering tumour-selective cell death. Preliminary 
difficulties of cancer therapy are the increasing therapeutic efficacy and the lowering 
toxicity related with the nonspecific accumulation of therapeutic agents in the non­
target cells (Weiss et al., 1990). A large variety o f natural compounds prompt 
pronounced anticancer effects and some of them have been used as traditional herbal 
medicine. Most therapeutic anticancer drugs demonstrate high toxicity and poor 
solubility in water due to their hydrophobicity, which are critical challenges for 
clinical applications (Wani et al., 1971). Chemotherapic agents are exerted in 
combination in order to suppress toxic side effects as well as to increase therapeutic 
index of anticancer agents. On the other hand, intravenous administration o f these 
molecules with organic solvents or surfactants causes either aggregation or 
insufficient drug doses at the tumor site. Therefore, the design o f novel delivery 
systems of these therapeutic agents without organic solvents has gained significant 
attention (Appendino, 1993). The work presented in this thesis has focused on 
cyclodextrin and hydrogel based novel drug delivery formulations for the 
chemotherapeutic agents paclitaxel, curcumin and cisplatin.
1.1. Paclitaxel
Paclitaxel (Figure 1.1) is one of the most vital anticancer compounds extracted 
from the bark of Taxus brevifolia (Wani et al., 1971). It is highly effective in the
treatment of various types of cancers, especially ovarian and breast cancers. 
Paclitaxel, the first o f a new class o f microtubule stabilizing agents, has been 
welcomed by National Cancer Institute (NCI) as one of the most major developments 
in cancer therapy of over the last 40 years.
Paclitaxel was isolated in 1966 ftom the bark of Pacific Yew Tree (Taxus 
brevifolia), one of the geographical varieties of yew. The quick revelation o f its 
important biological properties was postponed owing to problems in proving its 
complex molecular structure (Walji and MacMillan, 2007). Its pure form was able to 
be achieved in 1969 and its chemical structure was published in 1971. Paclitaxel was 
found after the screening of more than 1 2 0 0 0  natural compounds for anticancer 
activity (Panchagnula, 1998). Its cytotoxicity on various cell lines and the detection of 
its novel mechanism of action fuelled remarkable attention to start in vivo studies 
(Schiff and Horwitz, 1980). At the end of the NCI screening program, paclitaxel was 
the only molecule left to be tested in clinical trials among thousands o f molecules 
(Stephenson, 2002).
The value of paclitaxel was not understood for almost two decades, because of 
severe supply issues and formulation problems. In 1979, Susan Horwitz revealed that 
it has an exclusive mechanism which must be further stimulated (Panchagnula, 1998).
1.1.1. Chemistry of paclitaxel
The chemical name of paclitaxel is 5p,20-epoxy-l,2a,4,?p,10p,13a- 
hexahydroxytax-11 -en-9-one-4,10-diacetate-2-benzoate 13 ester with (2R,3S)-N- 
benzoyl-3-phenylisoserine (C47H51NO 14). Its molecular mass is 853.9 g/mol and its 
structure is different from other antineoplastic agents (Kingston, 1994).
O" NH O
OHÔ 9
Figure 1.1. Structure of paclitaxel (C47H51NO14).
Because of the small amounts of drug obtainable from the crude bark extract 
and the complex and unusual chemistry of paclitaxel to synthesize, clinical trials of 
paclitaxel advanced slowly. Yields are about 0.01% of the dry weight o f bark. Newer 
methods of extraction of paclitaxel in large-scale application using chloroform from a 
single reverse-phase column have increased yields to 0.04%. In order to achieve 1 kg 
of paclitaxel, roughly 3000 trees had to be sacrificed and it was only enough for 500 
patients (Blume, 1989). Although total synthesis of paclitaxel was achieved, the total 
chemical synthesis of paclitaxel on an industrial scale is very difficult and may not be 
feasible commercially (Jenkins, 1996). With the combination of the central eight 
membered carbocycle and complex arrangement of oxygen bearing stereo centers, 
taxol displays itself as one of the principal challenges to organic chemists .
1.1.2. Physical properties and pharmacokinetics of paclitaxel
Paclitaxel is a highly lipophilic and white to off-white crystalline powder. It is 
insoluble in water and its melting point is around 216-217 °C. Its disappearance from
plasma is determined to be biphasic. The commonly conventional dose is 
200-250 mg/m^ and administered as 3 and 24 h infusion. Pharmacokinetics of 
paclitaxel shows an extensive changeability. Terminal half-life is in the range of 1.3- 
8.6 h (mean 5 h) and the steady-state volume of distribution was found to be aroimd 
87.1 m~^. Less than 10% of paclitaxel in the same form is excreted in the urine. The 
molecule is eliminated mostly in feces. Around 95% of the molecule is bound to 
plasma protein and the volume of distribution is about 55 L/m^ (Wiemik et al., 1987). 
The highest concentration of the paclitaxel following a 6-h infusion in rats was found 
to be in the lung, liver, kidney, and spleen and was essentially excluded from brain 
and testes (Rowinsky and Donehower, 1993).
Its nonlinear pharmacokinetics has been attributed to saturable elimination 
(Sonnichsen et al., 1994) and a saturable distribution binding. Higher plasma 
concentration and particularly the duration of paclitaxel concentrations above a 
threshold directly affect the success o f the chemotherapy (Mielke et al., 2005).
1.1.3. Solubility of paclitaxel
Paclitaxel has poor solubility in water and is rapidly destroyed in weakly 
alkaline, aqueous solutions (Richheimer et al., 1992). Moreover, paclitaxel lacks 
functional groups that are ionisable in a pharmaceutically useful range and therefore a 
manipulation of pH does not improve its solubility. However, it can be dissolved in 
organic solvents. Its solutions can be prepared in millimolar concentrations in a 
variety of alcohols such as ethanol, tertiary-butanol as well as in DMSO. Its solubility 
in methanol is 50 mg/ml. It undergoes hydrolysis and transestérification in methanol. 
Paclitaxel is rapidly degregated in weakly alkaline, methanolic solutions and in
strongly acidic methanolic solutions. Additionally, common approaches to increase 
solubility such as the addition of charged complexing agents or producing alternate 
salts of the drug are not feasible in the case of paclitaxel (Straubinger, 1995). 
Paclitaxel (20 mg/ml) remains more active in cyclodextrin solutions than in buffer 
solutions of comparable pH. Water solubility is improved in the presence of 
cyclodextrin (Dordunoo and Burt, 1996).
1.1.4. Mechanism of action of paclitaxel
Microtubules have cylindrical structures and primarily composed of tubulin. 
They perform a number of cellular functions e.g. movement, food ingestion, sensory 
transduction, controlling the shape of cells, and spindle formation during cell division. 
Unlike other tubulin-targeting drugs such as colchicine that inhibit microtubule 
assembly, paclitaxel has a unique mechanism of action. It promotes the 
polymerization of tubulin dimmers to form microtubules and then stabilizes the 
microtubules by preventing their depolymerization (Panchagnula, 1998). (Figure 1.2) 
Paclitaxel mostly binds to microtubules, instead of tubulin dimers. The binding site 
for paclitaxel has been identified on the beta-tubulin(Rao et al., 1994) unlike the 
binding sites of colchicine, vinblastine and podophyllotoxin for GTP. The exact 
mechanism of action of the paclitaxel is not determined completely, it disorders the 
dynamic equilibrium in the microtubule system in the late G2 phase and M phase of 
the cell cycle, in that way impeding cell replication (Rowinsky and Donehower, 
1993).
Polymerization
Stabilized
M icrotubules
Promotes
Paclitaxel
MicrotubuiesTubulin Dimers
Prevents
Depolymerization
Figure 1.2. Mechanism of action of paclitaxel.
1.1.5. Paclitaxel dosage forms and problems
The low therapeutic index of paclitaxel is generally related with toxic side- 
effects. It should be only used when the potential benefits of paclitaxel therapy 
outweigh the possible risks. A review explaining various clinical features o f paclitaxel 
was published by Rowinsky and Donehower (Rowinsky and Donehower, 1993). 
Table 1.1 reviews the toxicities and common side effects of paclitaxel therapy.
Table 1.1. Summary of therapeutic efficacy and toxicities (Panchagnula, 1998).
(a) Tumors responding to paclitaxel:
Breast cancer, ovarian cancer, head and neck cancer, 
small cell lung cancer, colon cancer, multiple myeloma, 
melanoma
(b) Dose-limiting toxic effects:
Neutropenia, neurotoxicity, mucosities, hypersensitivity
(c) Different svstems:
Cardiovascular: Asymtomatic bradycardia, 
trioventricular conduction blocks, atrial arrhythmias,
Hematological: Neutropenia, thrombocytopenia 
Hypersensitivity: Dyspnea with bronchospasm, urticaria 
Neurotoxicity: Peripheral neuropathy, transient 
Gastrointestinal tract: Mucosities, nausea, vomiting, di­
arrhea
Hepatotoxicity: Elevation of liver function tests 
Others: Alopecia, myopathy, fatigue.
Paclitaxel is insoluble in aqueous solution and is therefore formulated in 50% 
ethanol and 50% Cremophore EL (a polyoxyethylated castor oil derivative) which is 
diluted with 5-20-fold in normal saline or dextrose solution (5%) for administration 
The solubility problem can be somewhat clarified by the structure of paclitaxel. 
Paclitaxel has some hydrophobic substituents. It does not have any functional 
ionizable group and, thus, pH change does not improve its solubility. The current
formulation is stable in unopened 5 ml size vials for 5 years at 4 °C. However, this 
ethanol -  Cremophore EL formulation caused several problems. Clinically, a 
significant issue is hypersensitivity reactions related with formulation. Studies have 
shown that the Cremophor EL vehicle induces histamine release and hypotension in 
dogs (Lorenz et al., 1977). Cremophor EL has also a deep effect on the 
pharmacokinetics and distribution of paclitaxel (Sparreboom et al., 1996). The other 
problem is stability of the drug product. Properly diluted paclitaxel is only stable for 
12-24 h. It must be administered within 12 h of dilution in the aqueous media. 
Further, it is determined that the chemical stability of paclitaxel could be changed due 
to the condition o f handling and administration.
1.1.6. Paclitaxel delivery
The main problem of paclitaxel during chemotherapy is the bioavailability of 
drug and its delivery. Paclitaxel is very hydrophobic and thus it is only very slightly 
soluble in an aqueous medium. Owing to this limited solubility, it is presently 
formulated in a delivery vehicle composed of 1:1 blend o f Cremophor EL 
(polyethoxylated castor oil) and ethanol, which is diluted in normal saline and 
dextrose solution (5%) before the intravenous administration. However, there are 
many limitations associated with the intravenous administration of the present 
formulation, for example, hypersensitivity, neurotoxicity, mucosities, elevation of 
liver function tests, and alopecia, just to name a few. Therefore, the present 
approaches (Figure 1.3) to enhance the therapeutic potential of paclitaxel mainly 
focused on the development of aqueous formulations for paclitaxel in order to 
eliminate the Cremophor EL and to overcome the related limitations in terms of
stability (Singla et al., 2002). These approaches include the use of liposomes, 
micelles, nanocapsules, polymeric microspheres, prodrugs, and bioconjugation with 
different molelcules, e.g., albumin, etc. Recently, the complexation of paclitaxel with 
cyclodextrins (CDs) has gained much attention for the improvement in solubility and 
stability of the paclitaxel (Panchagnula, 1998).
Structural Modification 
of Drug
Drug Complexations 
(with cyclodextrins, 
cyclodextrin dimer)
FORMULATION
APPROACHES
Carrier Mediated 
Approaches 
(liposomes, 
nanoparticles)
Increased Aqueous Solubility 
(co-solvency, émulsification)
Figure 1.3. Alternative approaches for paclitaxel formulation.
1.2. Curcumin
Turmeric is a bright yellow spice derived from the root of the perennial 
curcumin longa, a member of the ginger family. Curcumin is a polyphenolic 
compound that has been identified as the main hioactive component of turmeric and 
belongs to a family of compounds called curcuminoids which usually comprises about
10
3% of turmeric powder. This yellow coloured compound has a long history of human 
consumption as a natural pigment and was widely used for its culinary flavour as it 
gives curry its characteristic taste. For centuries, curcumin has been applied as 
medicine most likely because of its properties as an antiseptic, analgesic, agent, 
antioxidant, appetite suppressant, anti-inflammatory, anti-malarial and insect 
repellent(Araujo and Leon, 2001) in many regions of the world. In recent decades, 
curcumin has been discovered to be effective in preventing and treating chronic 
inflammatory diseases as well as cancer (Grant and Schneider, 2000).
1.2.1. History of curcumin
The history of curcumin goes back over 5000 years to the time o f Ayurveda 
which is the science of good life and an ancient system of healthcare practiced in 
India. The rhizome of perennial herb turmeric used in Asian medicine for centuries. It 
was ingested to treat a diversity o f disorders including rheumatism, body aches, skin 
diseases, wounds, intestinal worms, diarrhoea, leukoderma, amenorrhea, or mixed 
into a paste and applied topically to treat wounds, bruises, swellings and other 
disorders of the skin (Jagetia and Aggarwal, 2007). Besides, curcumin was used as a 
food preservative or additive for many years. Turmeric also used as cosmetics, 
particularly in Hindu rituals and ceremonies. In Europe, turmeric was also named 
Indian Saffron because of its colour and taste. Curcumin was first isolated from 
turmeric in 1815. Its chemical structure was determined by Vogel and Pellatier (Vogel 
and Pelletier, 1815;Sharma et al., 2005).
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1.2.2. Chemistry of curcumin
Turmeric is mainly composed of curcuminoids and volatile oils, including 
tumerone, atlantone and zingiberene. The bright yellow colour o f turmeric comes 
from curcuminoids, polyphenolic pigments. The major curcuminoids present in 
turmeric are curcumin, demethoxycurcumin and bisdemethoxycurcumin (Figure 1.4).
O O
H3CO
Curcumin (Curcumin I)
O O
OCH3
H3CO
HO' ^  ^  "OH
Demethoxy curcumin (Curcumin I!) 
Bisdemethoxy curcumin (Curcumin III)
Figure 1.4. Structure of three major curcuminoids in turmeric.
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Curcumin is a hydrophobic, polyphenolic compound that is soluble in ethanol, 
dimethyl sulfoxide, aeetone, chloroform and is insoluble in water. Curcumin 
[chemical name; (E-E)-l,7-bis (4-hydroxy-3-methoxyphenyl)-l,6-heptadiene-3,5- 
dione], also called diferuloylmethane, has a molecular weight of 368.39, a melting 
point of 179-183°C and chemical formula C21H20O6 (Aggarwal et ah, 2007). 
Curcumin can be found in both keto and enol forms, but the keto form is more 
energetically stable and a potent donor of protons. (Figure 1.5) On the other hand, in 
alkaline condition, the enolate form is predominant and the phenolic part o f curcumin 
plays the role of electron donor. Its absorption maxima is around 420 nm and 
therefore it fluoresces at the wavelength of FITC. Its analogs demethoxycurcumin and 
bisdemethoxycurcumin are commercially available, although curcumin is known be 
the most potent of the three (Ahsan et ah, 1999; Sreejayan and Rao, 1996).
Keto Form
Enol Form
Figure 1.5. Structure of curcumin in keto and enol forms.
13
1.2.3. Therapeutic potential of curcumin
Potential of curcumin has been extensively reviewed for the prevention of 
cancer in last decades. It is determined that it successfully inhibits the initiation, 
promotion, and progression of tumor during carcinogenesis, ascribing to its activities 
against inflammation, virus, and oxidation.
Curcumin inhibits proliferation of different cancer cell types both in 
vitro (Aggarwal et a l, 2003) and in vivo (Menon et ah, 1995). It affects with 
angiogenesis by inhibiting fibroblast growth factor (FGF) induced neovascularization 
and prevents vascular endothelial growth factor (VEGF) expression (Gururaj et ah, 
2002; Mohan et ah, 2000). Further, curcumin can show the anti-tumor effects by 
reducing adhesion molecule expression which is significant for tumor metastasis 
(Bhandarkar and Arbiser, 2007). Curcumin also modulates matrix metalloproteinases 
(MMPs) that regulate endothelial cell migration and attachment (Lin et ah, 1998). 
Curcumin also regulates the activity o f several enzymes like C0X2, 5L0X, iNOS by 
interacting directly and modulates gene transcription through the inhibition of 
transcription factors NF-kB, AP-I, Akt and Nrf2(Hatcher et ah, 2008) which regulate 
multiple signalling pathways. These pathways control cell proliferation, apoptosis, the 
production of cytokines and other inflammatory mediators.
Effect o f curcumin has been presented in different types o f animal models and 
human studies to be exceptionally safe even administered at high doses (Cheng et ah, 
2001; Lao et ah, 2006). Curcumin was first tested in a mouse model, in which animals 
were injected with Dalton’s lymphoma cells before the treatment o f curcumin. A 
considerably enlarged ratio of cancer-free survival was detected in animals treated 
with curcumin, compared with controls (Kuttan et ah, 1985). Further animal studies
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supported the chemo-preventive features of curcumin in various organs, such as 
breast, stomach, prostate, and colon (Chen et ah, 2005; Kawamori et ah, 1999).
The anticancer effect of curcumin was also investigated statistically by 
epidemiologists (Chauhan, 2002). The ratio of colorectal cancer is fairly lower in 
countries with a high consumption of curcumin, comparing to countries where 
curcumin consumption is low. Furthermore, the second generations o f migrants from 
Eastern regions to the Western world display a higher risk for colorectal cancer than 
their first-generation ancestors, support the theory that the lower consumption of 
curcumin in their diet in the Western countries.
1.2.4. Therapeutic limitations of curcumin
Despite its efficacy and safety, curcumin shows very low bioavailability with 
poor absorption and rapid metabolic elimination (Anand et ah, 2007; Suresh and 
Srinivasan, 2007). The low concentration of curcumin in serum was detected in an 
early study, in which rats were given curcumin orally (Wahlstrom and Blennow, 
1978). It was mainly attributed to the poor absorption of curcumin due to insolubility 
in water, rapid systemic elimination in the bile and urine. Not all compounds can be 
absorbed well through the mechanism of oral administration, indeed, 40% of 
curcumin orally administered is expelled unchanged in the feces. Its intraperitoneal 
administration on animals also resulted in rapid clearance of curcumin (Pan et ah,
1999). Another study has displayed the increased metabolism of curcumin as an 
important factor causing its poor bioavailability, besides the reduced absorption of 
this compound. Most of the absorbed curcumin is metabolized via glucuronidation to
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glucuronide and glucuronide/sulphate metabolites in the intestinal mueosa and the 
liver causing the increase of its water solubility, and subsequent excretion by the 
kidneys (Shoba et ah, 2007).
To solve the bioavailability problem and certain drawbacks of curcumin in 
chemotherapy, several methods have been considered, for instance structural 
modification, cyclodextrin complexation, loading into hydrogels, adding adjuvant, 
liposomal curcumin, curcumin nanoparticles and phospholipid complex.
1.3. Cisplatin
Cisplatin is a drug that is used to treat, but its use is limited by intrinsic or 
acquired resistance and severe side effects subsequent to increased dose (Giaeeone,
2000). Cisplatin (cA-diamminediehloroplatinum(II)) is a platinum-based 
chemotherapeutic drug used in chemotherapy to treat solid tumours, such as testicular, 
ovarian, bladder, stomach, head, neck and non-small cell lung cancer. It is a simple 
inorganic compound and its chemical structure in 2D and 3D is displayed in Figure 
1.6. Cisplatin is a square-planar molecule with two chloride ions and two ammine 
groups bound to a tetravalent platinum atom in the, cis arrangement (Kelland, 2007).
CIx ,„p .^,,oNH3
cr "NH
Figure 1.6. The chemical structures of cisplatin in 2D and 3D.
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1.3.1. History of cisplatin
Cisplatin is a chemical compound discovered in 1844 and was only found to 
have anticancer properties in 1970s by accident. Cisplatin was first synthesized by M. 
Peyrone in 1844. Its chemical structure was first clarified by Alfred Werner in 1893. 
It was rediscovered by Barnett Rosenberg a biophysicist at Michigan State University 
in fortunate experiment investigating whether electric fields played a role in cellular 
division. It was observed that the "field" was toxic when the electrical potential was 
formed across inert platinum electrodes but not when other inorganic compounds 
were used as electrodes (Rosenberg et ah, 1965). It was determined that the bacteria 
grew into an elongated form, and surprisingly, stopped to divide. Later a platinum 
compound formed in a reaction between the platinum electrodes and components of 
the solution was discovered as the source of inhibition of division. This fortunate 
discovery was triggered some other studies to investigate the effects o f platinum 
compounds on cell division. The mechanisms of cisplatin-induced cell death and the 
resistance mechanisms was investigated in the 1960-1970s and reviewed by the 
Rosenberg (Mareu et ah, 2005; Rosenberg, 1985; Wemyj and Morin, 2004). To this 
end, the platinum(II) complex, cz5-[PtC12(NH3)2], and the platinum(IV) complex, cis- 
[PtC14(NH3)2], were examined against Sarcoma 180 tumours in Swiss white mice. 
Both compounds displayed significant effect for the lessening large solid tumours. 
After the treatment the mice survived and did not indicate any signs of tumor 
(Rosenberg and Vancamp, 1969, 1970). Cisplatin was approved by the Ameriean 
Food and Drug Administration (FDA) in 1978 as the first member o f its class and it 
has been extensively used antineoplastics in the world.
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After success of eisplatin thousands of platinum derivatives have since been 
studied and assessed as potential anticancer molecule agents, although few of them 
were accepted for clinical use (Hambley, 1997). Especially, the analogues o f cisplatin 
like carboplatin and oxaliplatin was achieved and are applied effectively for the 
treatment of different tumour types (Giaeeone, 2000; Ferguson and Pearson, 1996; 
Loehrer And Einhom, 1984). Currently, worldwide annual sales o f platinum-based 
chemotherapeutic agents are around two billion U.S. dollars (Siafaca, 1999).
1.3.2. Mechanism of action of cisplatin
The main effect o f cisplatin on tumour cells occurs with formation of 
cisplatin-DNA adducts which interfere with cellular repair and replication by 
inhibiting DNA synthesis and result in cell death. The cisplatin uncharged is able to 
enter cancer cells through the cell membrane (Gately and Howell, 1993). The chloride 
concentration in the cell is fairly low and therefore one o f the chloro ligands o f the 
cisplatin is substituted by water, producing a reactive and positively charged species 
that cannot willingly leave the cell. The charged, active, aquated species can be easily 
attacked by various macromolecules having nucleophilic groups, including DNA. 
The Pt-DNA adducts are supposed to be responsible for killing the cell. In vitro 
studies have shown that this monoaquated platinum species is able to bind at least 
98% of the platinum to DNA in the cell nucleus (Davies et al., 2000). Cisplatin is a 
generally bifunctional agent which can bind to two sites in DNA. The primary 
biftinctional adducts are guanine-guanine and adenine-guanine(Cohen et al., 1980), 
initiating significant distortion of the DNA that can be recognized by one or more 
DNA binding proteins. These proteins can either induce DNA damage repair or
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apoptosis (Fuertes et al., 2002; Kelland, 2000). Besides, in vitro studies have showed 
that interaction between the cisplatin molecule and the DNA may cause the formation 
of superoxide radicals, initiating further toxicity to cancer cells (Masuda et al., 1994; 
Tanaka-Kagawaetal., 1999).
1.3.3. Therapeutic limitations of cisplatin
In addition to its anticancer activity, cisplatin is severely toxic against healthy 
tissues and cause extreme side effects. Major side-effects determined in clinical 
practices are renal toxicity, nephrotoxicity, neurotoxicity, ototoxicity, severe nausea, 
bone marrow suppression, infertility and vomiting (Cooley et al., 1994). Moreover, 
the International Agency for Research on Cancer (lARC) has classified cisplatin as a 
probable human carcinogen. Furthermore, acquired resistance can develop against 
cisplatin in some types of tumours during the treatment process, which reduces the 
clinical efficacy o f cisplatin. All side effects and limitations o f cisplatin have 
encouraged investigations o f new drug formulations of cisplatins to have better 
clinical activity and reduce cytotoxicity o f the drug.
1.3.4. Combination therapy of cisplatin
The efficacy of cisplatin is considerably improved when used with other 
chemotherapeutic drugs in combination and/or radiation therapy. Accordingly, 
cisplatin/radiation or combination chemotherapy is the landmark for treatment o f 
many cancers. Clinicians have tested extensively in combining platinum-based
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chemotherapy with other anticancer agents. For instance, the combination of cisplatin 
and cetuximab was synergistically effective in the treatment o f metastatic/recurrent 
head and neck cancer. Combination treatment with cisplatin and radiotherapy have 
been demonstrated to be more effective than radiotherapy alone on non-small cell 
lung cancer and various squamous cell carcinoma patients (Crissman et ah, 1987; 
Hazuka et al., 1994).
1.4. Cyclodextrins
Enzymatic degradation of starch by the extracellular microbial enzyme 
cyclodextrin glycosyltransferas produces a mixture of cyclic and linear 
oligosaccharides. The cyclic oligosaccharides, indicated as cyclodextrins (CDs), are 
composed of a number of (l-^4)-linked a-D -glucose units of which CDs with six, 
seven, and eight glucose units are well known as a-, P-, and y-CD, respectively. 
CGTases primarily produce a-, p-, and y-CD and only a small fraction o f large CDs 
are formed (Tonkova, 1998).
Owing to the low solubility of the native a-, p-, and y-CD, a high number of 
derivatives of these molecules have been synthesized (Szejtli and Fromming, 1994). 
New CD derivatives typically display altered features with respect to solubility, 
biocompatibility, and complex formation.
The main attention in CDs and their derivatives focuses on their ability to 
make inclusion complexes with a wide range of molecules, mediated by a 
hydrophobic cavity surrounded by a hydrophilic outer shell (Figure 1.7). The 
inclusion complexes of CDs can alter the biochemical and physicochemical features
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of the guest molecule. Examples of effects obtained by encapsulation with CDs are 
altered solubility, reduced volatility, modified chemical reactivity, protection against 
degradation, and improved bioavailability of the included molecule (Figure 1.8). 
Moreover, CDs are considered as some of the most important building blocks for 
supramolecular structures and functional units in supramolecular chemistry and 
nanotechnology. Table 1.2 shows the general properties of CDs.
Table 1.2. General features of CDs (Del Valle, 2004).
Property a -
Cyclodextrin
P"
Cyclodextrin
Y-
Cyclodextrin
Number of glucopyranose 
units 6 7 8
Molecular mass (g/mol) 972 1135 1297
Solubility in water at 25 ”C
(%, w/v) 14.5 1.85 23.2
Outer diameter (nm) 1.46 1.54 1.75
Cavity diameter (nm) 0.47-0.53 0.60-0.65 0.75-0.83
Height of torus (nm) 0.79 0.79 0.79
Cavity volume (nm^) 0.174 0.262 0.427
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OH Secondary 
hydroxyl rim
Hydrophobic 
cavity \HO OH HO
HO
HO OHOH
OHHO
OH
Primary hydroxyl rim
HO
(a) (b)
Figure 1.7. p-Cyclodextrin: structure o f (3-cyclodextrin (a), functional scheme of the 
cyclodextrin (b) p-Cyclodextrin is the most commonly used cyclodextrin because of 
its appropriate cavity size and due to the lowest price.
Figure 1.8. Water molecules in the cavity of p-CD. It is obtained by Spartan- 
Computer modeling. There is space for 11 water molecules in the cavity of p-CD.
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1.4.1. Cyclodextrin polymers
Polymers containing a number of covalently linked CDs are defined as CD 
polymers. The CD polymers behave differently comparing to their monomers 
(Atwood and Lehn, 1996). Classification o f the CD polymers is presented in Figure 
1.9: (a) linear polymers, (b) cross-linked polymers, (c) CDs immobilized by covalent 
bond to macromolecular support, (d) CDs immobilized by physical bonding in/to 
macromolecular support and (e) necklace-type CD polymers (polyrotaxanes). CD 
polymer (c) mean that CDs was able to be immobilized by covalent bonds. Both the 
support and CD must be covalently altered before the immobilization. CD polymer
(d) is not an actual CD polymer according to the definition, because CDs are not 
covalently linked. Extraordinary sorts of CD polymers are achieved when monomer 
CD complexes are polymerized as displayed Figure 1.9 (e) (Bachmann et al., 1998).
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(a) (b)
(c)
(4)
(e)
&
Figure 1.9. Scheme of the main types of CD polymers.
(a) Linear polymer
(b) Cross-linked polymer
(c) CDs immobilized by covalent bond to a macromolecular support
(d) CDs immobilized by physical bonding in/to a macromolecular support
(e) Polyrotaxane CD polymer
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1.4.2. Inclusion properties of CDs
Inclusion complexes are composed of two or more molecules, in which one of 
them is the host, can admit a guest component into its cavity. A stable encapsulation 
is achieved without formation of any covalent bond (Saenger, 1980; Smolkova- 
Keulemansova and Krysl, 1980). Inclusion is specific spatial interaction. In analytical 
chemistry, inclusion complexation particularly is used in chromatographic 
separations.
During the complexation process, the guest enters into the CD cavity from 
wider and accessible side to get into maximum contact with the hydrophilic surface of 
the CD molecule. The complex formation between the host and a guest molecule, 
defined as S, is a dissociation-association equilibrium process that can be displayed 
with the following equation(Bender and Komiyama, 1978; Hinze, 1981):
CD + S ^ C D S  (1)
" " W  ®
where [CD * S] is the concentration of the substrate complexed with the CD. [CD] 
and [S] represent the free concentration of the uncomplexed CD and substrate 
molecule, respectively. The greater the Kf value, the more stable is the CD inclusion 
complex.
A number of factors affects the inclusion complex formation and some 
interactions were determined between host and guest molecule:
a) Hydrophobic effects: It initiates the nonpolar molecule to specially enter the 
CD cavity.
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b) Van der Waals interactions: These interactions include interactions between 
permanent and induced dipoles and London dispersion forces.
c) Hydrogen bonding: It is between guest molecule and the secondary hydroxyl 
groups and the rim of the cavity.
d) Steric effect: Complexation process is also affected by shape, size ,and 
polarity of the guest molecules.
e) Solvent effect: Release of high-energy water.
Generally, combination of these effects was anticipated to clarify inclusion 
phenomena. The most common host-guest stoichiometries are 1:1, 2:1, and 1:2. 
Complex formation is characterized with various techniques such as UV-Visible 
absorption, fluorescence, NMR, IR, and Raman spectroscopy. X-ray analysis, DSC, 
TGA, and electrochemistry (Bender and Komiyama, 1978).
1.4.3 Complexation techniques
There are six common techniques which are used to form cyclodextrin 
complexes (Hirayama and Uekama, 1987; Loftsson and Brewster, 1996).
I.4.3.I. Co-precipitation
This is the most widely used method in the laboratory. Cyclodextrin is 
dissolved in water and the guest molecule is added while stirring the cyclodextrin 
solution. The concentration of p-cyclodextrin can be as high as about 20% if  the guest 
can tolerate higher temperatures. The cyclodextrin solution and guest molecule have
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to be cooled while stirring. The precipitate can be collected by centrifugation or 
filtration. The foremost disadvantage of this method is at the scale-up, because large 
volumes of water have to be used (Loftsson et al., 1993).
1.4.3.2. Slurry complexation
Cyclodextrin can be added to water and stirred. The solution is saturated with 
cyclodextrin. The cyclodextrin complex saturates the water phase and the formed 
complex will precipitate out of the aqueous phase. The complex can be achieved in 
the same manner as with the co-precipitation method.
I.4.3.3. Paste complexation
This method is similar to slurry method but a small amount of water is added 
to form a paste, which is mixed to the cyclodextrin using a mortar.
1.4.3.4. Damp mixing and heating
In this method little or no water is used. The guest molecule and cyclodextrin 
are completely mixed and heated to about 100°C. The contents are removed and 
dried.
1.4.3.5. Extrusion
Extrusion is a combination of the heating and mixing method and is a 
continuous system. Cyclodextrin, the guest, and water can be premixed or mixed and
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added to the extruder. The degree of mixing, amount of heating, and time can be 
controlled in the barrel o f the extruder. Extrusion has the advantages o f being a 
continuous process and using very little water. Because o f the heat generated, some 
heat-labile guests decompose using this method.
1.4.3.6. Dry mixing
Some guests can be complexed by simply adding guest to the cyclodextrin and 
mixing them together. This works best with oils or liquid guests. The primarily 
advantage is that no water or any other solvent is required (Del Valle, 2004).
1.5. Hydrogels
1.5.1. Introduction to hydrogels
Hydrogels are three-dimensional, hydrophilic, polymeric networks capable of 
absorbing large amounts of water (Brannon-Peppas, 1990; Peppas, 1987). Hydrogels 
have appealed remarkable research curiosity due to the potential for a wide range of 
applications. Hydrogels are used in tissue engineering and drug delivery applications, 
by reason of their good resemblance to natural living soft tissues, and their 
biocompatibility (Davis and Anseth, 2002; Lin and Metters, 2006; Peppas et al., 
2006). These networks are composed of homopolymers or copolymers and insoluble 
in water, due to the presence of chemical crosslinks, covalent bonds, or physical 
crosslinks, such as hydrogen bonds, hydrophobic interactions, or ionic interactions 
(Bryant and Anseth, 2002; Mason et al., 2001).
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Hydrogels can be divided into two categories with regards to their natural or 
synthetic origins. Natural polymers forming hydrogel include proteins such as 
collagen and gelatin, and polysaccharides such as alginate and agarose. Synthetic 
origin hydrogels are usually prepared by chemical polymerization of hydrogel 
monomers which are presented in Table 1.3. (Peppas et al., 2000).
Table 1.3. The most common hydrogel monomers for pharmaceutical applications.
Abbreviation Monomer
HEMA Hydroxyethyl methacrylate
HEEMA Hydroxyethoxyethylmethacrylate
HDEEMA Hydroxydiethoxyethylmethacrylate
MEMA Methoxyethyl methacrylate
MEEMA Methoxyethoxyethylmethacrylate
MDEEMA Methoxydiethoxyethylmethacrylate
EGDMA Ethylene glycol dimethacrylate
NVP N-vinyl-2-pyrrolidone
NIPAAm N-isopropyl AAm
VAc Vinyl acetate
AA Acrylic acid
HPMA N-(2-hydroxypropyl)methacrylamide
EG Ethylene glycol
PEGA PEG acrylate
PEGMA PEG methacrylate
PEGDA PEG diacrylate
PEGDMA PEG dimethacrylate
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Hydrogels display thermodynamic features with water which allows them to 
swell in aqueous media. Physical crosslinks can be disordered by an alteration in the 
environmental conditions, such as the temperature, pH, electric field, pressure, and the 
application of stress (Hatefi and Amsden, 2002; Qiu and Park, 2001). If  the physical 
crosslinks are disrupted, a free flowing fluid, a sol, is formed. This sol to gel 
transition, which can be fully reversible, creates opportunities to use such materials as 
injectable systems (Packhaeuser et al., 2004).
1.5.2. Thermo-responsive hydrogels for pharmaceutical applications
In last years, stimuli-sensitive hydrogels have gained interest because o f their 
smart features related with the environmental stimuli and good biocompatibility. 
Particularly, thermosensitive physically crosslinked hydrogels consisted of 
hydrophobic and hydrophilic blocks have been extensively studied because o f their 
potential biomedical applications in in situ gel-forming novel drug delivery systems. 
These hydrogels are pharmaceutically well recognized due to several of temperature 
sensitive drugs being administered in these dosage forms. The release behaviour of 
drug and hydrogels could be adjusted with the variation in the temperature o f external 
environment (Prabaharan and Mano, 2006).
Thermo-responsive hydrogels based on biodegradable copolymers with the 
hydrophobic and hydrophilic block can be classified into two groups:
(1) Hydrogels that are sol at low temperatures and turn into gel with rising 
temperatures. Raising the temperature further leads to a sol phase again (Figure 
1.10. A).
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(2) Hydrogels that are gel at low temperatures and form a sol with rising 
temperatures (Figure 1.10.B).
Soli
1
o-
I Gel
Sol
Copolymer Concentration in water
Sol
Gel
Copolymer Concentration in water
Figure 1.10. The transition diagrams of copolymers in water that display (A) sol-gel- 
sol transitions (class 1), and (B) gel-sol transitions (class 2),
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Thermo-responsive hydrogels include at least one temperature sensitive group. 
The structures o f some synthetic hydrogel components used for the preparation of 
thermo-sensitive hydrogels are displayed in Figure 1.11.
Synthetic non-degradable
PNIPAAM PPO PEO
Synthetic degradable
PGA
n  *  *
A,
o
PMGA
Figure 1.11. Molecular structure of hydrogel forming polymers or copolymer 
building blocks.
Tanaka (Tanaka, 1978) developed the thermo-sensitive hydrogels of 
PNIPAAM (polyisopropylacrylamide) which is a distinguished synthetic polymer and 
show thermo-responsive gelation in water. PNIPAAM displays a lower critical 
solution temperature (LCST) at approximately 32 °C that can be adjusted to body
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temperature by the integration of other hydrogel components. However, the use of 
PNIPAAM has serious limitations because of its known cytotoxicity (Vihola et al., 
2005).
The other well-known types o f temperature sensitive copolymers include 
poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO). These components are 
identified under the commercial names of Pluronics and Poloxamer. Poloxamer is 
composed of hydrophilic ethylene oxide (EO) and hydrophobic propylene oxide (PO) 
blocks, arranged in a tri-block structure of EOa-POy-EOa (PEO-PPO-PEO) where a 
and b chain lengths vary from 2-130 and 16-70 units, respectively. This structure 
results in amphiphilic copolymers that self-assemble into spherical micelles in 
aqueous solutions above critical gelation temperature and concentration (Hatefi and 
Amsden, 2002). The core is formed by the hydrophobic interaction o f the PO block 
and stays separated from the aqueous exterior by the hydrophilic corona formed by 
EO blocks. Poloxamer components rise phase separation, which is due to the 
complete dehydration of both PO and EO blocks (Goldstein, 1984). PEO-PPO-PEO 
copolymers demonstrate characteristics of both a lower sol-gel transition and an upper 
gel-sol transition with elevated temperature (Mortensen et al., 1994; Wanka et al., 
1994). The PEO-PPO-PEO block copolymers are offered in a range o f molecular 
weights and PPO/PEO ratios and thus, their physical and surface properties vary over 
different types (Alexandridis and Alan Hatton, 1995). Poloxamers are able to alter 
their structure from individual block copolymer molecules to self-assembling 
micelles.
The arrangement of different PEO-hydrophobic block causes several micelle 
systems with varying physicochemical properties against different type o f drugs.
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Polymeric micelles made of poloxamer block copolymers (poloxamer) are 
biocompatible and have been proven to be suecessfhl candidates for effectively 
carrying hydrophobic drugs. Poloxamer is approved by FDA for pharmaceutical and 
medical applications (Bonacucina et al., 2011).
The physically cross-linked gel structure has been widely used for drug 
delivery carrier because it shows exceptional sol-gel transition behaviours in response 
to temperature in aqueous solution. The hydrophobic core of such micelles functions 
as a cargo space for carrying non-polar therapeutic compounds, while the hydrophilic 
corona enhances the pharmaceutical behaviour of block copolymer. The non-covalent 
incorporation of drugs with the hydrophobic PO core o f the Pluronic micelles results 
in increased solubility, metabolic stability, bioavailability, and circulation time. In 
addition, Pluronic block copolymers have demonstrated enhanced therapeutic activity 
of many chemotherapeutic agents such as paclitaxel, and cisplatin (Exner et al., 2005; 
Guo et al., 2007; Guo et al., 2009).
1.6. Aim and Objectives
The general aim of the proposed researeh thesis was to investigate novel drug 
formulations for ehemotherapy in order to enhanee therapeutic activity o f anticancer 
agents and suppress their toxie side effects.
The speeific objeetives to achieve the overall aim are as follows:
1. To design a novel derivative of p-eyclodextrin to improve the water solubility, 
stability and bioactivity of paclitaxel for therapeutie applieations.
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2. To prepare a P-cyclodextrin polymer to enhance water solubility and stability 
o f curcumin and paclitaxel as well as their therapeutic activity alone and in 
combination for various cancer models.
3. To synthesize a novel derivative o f poloxamer hydrogel to enhance 
chemotherapeutic effects of curcumin and cisplatin alone and in combination 
for different cancer types.
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Chapter 2
Enhancement of Bioactivity of 
Paclitaxel by p-Cyclodextrin-L- 
Glutamic Acid Encapsulation
This chapter has been submitted to Inclusion Phenomena and Macrocyclic Chemistry 
A.O. Boztas et ah, Enhancement of Bioactivity o f Paclitaxel by P-Cyclodextrin-L- 
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2.1. Abstract
Paclitaxel is an anticancer agent with poor water-solubility. It is widely 
employed for the therapy of different cancer types. The current formulation for the 
intravenous administration involves a non-aqueous vehicle which may cause allergic 
reactions and precipitation on aqueous dilution. In this study, the encapsulation of 
paclitaxel with a novel L-glutamic acid derivative of p-cyclodextrin (CD-Glu) was 
investigated in order to improve its water-solubility, stability and bioactivity of 
paclitaxel for therapeutic applications. The new paclitaxel/CD-GLU complexation 
was tested on A2780, SKOV-3, H1299, DU-145 and MCF-7 cell lines. Cell viability 
and colony formation assays revealed that CD-Glu encapsulation significantly 
enhances the cytotoxicity of paclitaxel on all cell lines except breast cancer cells 
(MCF-7). Annexin V apoptotic studies showed that paclitaxel induced apoptosis in 
A2780, SKOV-3, H I299 and DU-145 cell lines were significantly improved after 
CD-Glu encapsulation. Complexes prepared in the solid phase were found to exhibit 
higher water-solubility compared to those prepared in the liquid phase. Overall, our 
results demonstrate the delivery of paclitaxel via CD-Glu encapsulation as a 
promising method for increased therapeutic effects.
P a c  i t a x e l
L - G l u t a m i c
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2.2. Introduction
Paclitaxel (Figure 2.1) is one of the most vital anticancer compounds and is 
extracted from the bark of Taxus brevifolia (Dordunoo and Burt, 1996) It has been 
known to be highly effective in the treatment of various types o f cancers, especially 
ovarian and breast cancers. Paclitaxel has a unique mechanism of action as it 
promotes the polymerization of tubulin dimmers to form microtubules and then 
stabilizes the microtubules by preventing their depolymerization (Panchagnula, 1998).
O" NH O
O H Ô  9
Figure 2.1. Structure of paclitaxel.
Paclitaxel is highly hydrophobic and thus it is only very slightly soluble in an 
aqueous medium. Owing to this limited solubility, it is presently formulated in a 
delivery vehicle composed of 1:1 blend o f Cremophor EL (polyethoxylated castor oil) 
and ethanol, which is diluted in normal saline and dextrose solution (5%) before the 
intravenous administration. However, there are many limitations associated with the 
intravenous administration of the present formulation, such as, hypersensitivity, 
neurotoxicity, mucosities, elevation of liver function tests and alopecia. Therefore, the 
present approaches to enhance the therapeutic potential o f paclitaxel mainly focus on
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the development of aqueous formulations for paclitaxel in order to eliminate the 
Cremophor EL and overcome the related limitations in terms of stability (Singla et al., 
2002). These methods include the use of liposomes, micelles, nanocapsules, 
polymeric microspheres, prodrugs, and bioconjugation with different molelcules, e.g., 
albumin. Recently, the complexation of paclitaxel with cyclodextrins (CDs) for the 
improvement in solubility and stability of paclitaxel has gained much attention 
(Panchagnula, 1998).
Cyclodextrins (CDs) are oligosaccharides composed of six or more D-gluco- 
pyranose residues attached by a-1,4-linkages in a cyclic array. The encapsulation of 
guest molecules in CDs leads to a change in their physicochemical properties and can 
result in increased stability, solubility, bioavailability and tolerability, (Jarho et al., 
1996) as well as in the elimination of negative side-effects (Ertan et al., 2008). In 
addition to these advantages, the majority of drugs form 1:1 complexes with various 
CDs (Horvath et al., 2008). The most current CDs contain six, seven, or eight glucose 
residues and are named a-CD, P-CD, and y-CD, respectively (Li et al., 2004; Davis 
and Brewster, 2004). The internal cavity, which is highly hydrophobic, can 
accommodate a wide range of guest molecules, ranging from polar compounds, such 
as alcohols, acids, amines, and small inorganic anions, to nonpolar compounds, such 
as aliphatic and aromatic hydrocarbons (Hirayama and Uekama, 1999; Hapiot et al., 
2006). However, the enhancement of the water-solubility o f paclitaxel by pristine 
CDs is fairly limited (Sharma et al., 1995). Therefore, if  further enhancement o f the 
solubility of paclitaxel is contemplated with CD complexation then it is necessary to 
conjugate the CDs with other functional groups (Lee et al., 2001).
L-Glutamic acid is nontoxic and it is one of the two amino acids that contain a 
functional carboxylic acid group in its side chains. Previously, its polymers were
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investigated as drug carriers. For instance, poly(L-glutamic acid) - paclitaxel 
conjugates produce fewer apoptotic cells but more extensive tumor necrosis in 
comparison to pure paclitaxel (Li et al., 1998).
In this work, we report the complexation of paclitaxel with a novel L-glutamic 
acid derivative of p-cyclodextrin (CD-Glu). CD-Glu has a high water-solubility and 
can help to increase the solubility, stability and therapeutic activity of paclitaxel upon 
complexation. The bioactivity o f paclitaxel/ CD-Glu complexes was assessed on 
ovarian, lung, prostate and breast cancer cell lines by three different methods.
2.3. Materials and methods 
Materials
Paclitaxel and glutaraldehyde were purchased from Alfa Aesar (Heysham, 
Lancashire, UK). L-Glutamic acid monosodium salt hydrate and ethanol were 
supplied from Sigma-Aldrich (St. Louis, MO). The triazine derivative of P- 
cyclodextrin was supplied by CTD Inc. (High Springs, FL) and used without further 
purification. Crystal Violet was from Alfa Aesar (Ward Hill, MA). Dimethyl 
sulfoxide was purchased from VWR (West Chester, PA). DMEM medium, RPMI 
1640 medium and trypsin EDTA were from Cellgro (Manassas, VA) and PE Armexin 
V Apoptosis Detection Kit I was purchased from BD Pharmingen (San Diego, CA).
Synthesis of CD-Glu
An aqueous solution (5 wt%) of Glutamic acid monosodium salt hydrate
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(1.12 g) was added dropwise to 5% solution (pH 11) of p-cyclodextrin triazine (2.34 
g) under stirring for 2 h in an ice-water bath. Then the mixed solution was reacted at 
room temperature for 12 h under magnetic stirring. Reaction was stopped by 
neutralization with an aqueous hydrochloric acid solution (0.1 M). The resulting 
solution was purified by ultrafiltration (nominal molar mass exclusion limit of 
1 kg mol'^). The final solution was freeze dried at -50 °C and at 1 mbar after being 
frozen at -80 °C. After freeze drying, a white amorphous powder was obtained.
CD-Glu was characterized with ^H-NMR and mass spectroscopy. ^H-NMR 
spectroscopic analyses performed with Varian 300 MHz superconducting NMR with 
deuterated dimethyl sulfoxide (DMSO-<76) as the solvent at 22 °C. Mass spectra was 
recorded on a Waters Xevo TOF mass spectrometer fitted with an electrospray ion 
source.
Complexation of CD-GIu with Paclitaxel
10 mg of paclitaxel was dissolved in 12 ml of absolute ethanol and 95 mg of 
CD-Glu was dissolved in 12 ml o f water. CD-Glu solution was added to paclitaxel 
solution. Final solution was stirred for 5 h at room temperature. After ethanol 
evaporated the mixed solution was centrifuged to remove the uncomplexed paclitaxel. 
The supernatant was then frozen and lyophilized to obtain a white amorphous powder.
Quantification of paclitaxel
The concentration of paclitaxel in CD-Glu complexes was determined by 
HPLC, (Shimadzu Prominence with LC-20AD Pumps) consisting a photodiode array
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detector and Cig column (Shimadzu VP-ODS 250x4.6). Paclitaxel was monitored at 
227 nm with a methanol:water (70:30, v:v) of mobile phase, 1 ml/min of flow rate and 
35 °C of oven temperature. A 20 pL of paclitaxel was injected into the HPLC for each 
analysis.
Phase Solubility Analysis
The phase solubilities of paclitaxel was examined by the method reported by 
Higuchi and Connors (Higuchi and Connors, 1965). Different concentrations o f CD- 
Glu solutions (ranging 0.5-12 %, w/v) were prepared in water:ethanol (50:50, v:v) 
solution and filled in bottles. Excess paclitaxel was added to these solutions to attain 
saturation. Each bottle was capped and agitated for 5 h on a shaker at 22±0.5°C. The 
samples were withdrawn from the vials and filtrated through a 0.45 pm filter. The 
resulting clear solutions were diluted and analyzed by HPLC. All measurements were 
done in triplicate and the samples were protected from light. The phase solubility 
diagram was constructed by plotting concentrations o f dissolved paclitaxel against 
cyclodextrin concentration. In the case of the formation o f a 1:1 inclusion complex, 
the stability constant Kc can be obtained from the slope and intercept So o f the initial 
straight line portion of the diagram based on the equation described by Higuchi and 
Connors (Higuchi and Connors, 1965):
slope^K  =
Cell Culture
Human mammary adenocarcinoma MCF-7 cells and human prostate
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carcinoma DU-145 cells were propagated in DMEM medium. Human ovarian cancer 
cell lines SKOV-3 and A2780, and human nonsmall cell lung carcinoma cell line 
H I299 were maintained in RPMI 1640 in a 37°C humidified atmosphere containing 
95% air and 5% 00%. Both DMEM and RPMI-1640 media were supplemented with 
10% PBS, 2 mM L-glutamine, ImM sodium pyruvate, 100 I.U./ml Penicillin and 100 
pg/ml Streptomycin.
Cytotoxicity with Single and Combination Therapy
I tested the cytotoxic activity of the as-prepared inclusion complex and the 
parent drugs using five different cancer cell lines A2780, SKOV-3, H1299, DU-145 
and MCF-7. The cells were plated at 3000 cells/well into 96-well tissue culture plates 
(Coming Glass Inc., Corning, NY) and incubated at 37°C in a humidified atmosphere 
containing 5% CO2. After a 24 h recovery, cells were either untreated or treated for 72 
h with free dmg and the CD-Glu formulations containing graded concentrations of 
paclitaxel. Subsequently, cells received no further treatment. The cytotoxicity was 
measured using the MTT (Tsoli et al., 2005) [3-(4,5-dimethyl-2-thiazolyl)-2,5- 
diphenyl-2/7-tetrazolium bromide] cell survival assay (colorimetric method), wherein 
a tétrazolium compound is reduced to a formazan compound by living cells. The cell 
viability was evaluated by measurement of the absorbance at 570 nm. Eight replicates 
were made for each test condition, and plates were incubated for 3 days. The IC50 
values were defined as the concentration of dmg that produces 50% of cell growth 
inhibition.
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Colony Formation Assay
Colony Formation Assay of cells in vitro was performed for the five human 
cancer cell lines, A2780, SKOV-3, H1299, DU-145 and MCF-7. The cancer cells 
were seeded into 6-well plates in triplicates at a density of 1,000 cells/well in 2 ml of 
medium containing 10% FBS and allowed 3 day to initiate the colonies. These cells 
were treated with 1, 4, 7 nM of paclitaxel or paclitaxel/CD-Glu and incubated for 11 
days in a 37°C humidified atmosphere containing 5% CO2. The plates were rinsed 
with PBS. A mixture of 6.0% glutaraldehyde and 0.5% crystal violet was then added 
and left for at least 30 min. The glutaraldehyde - crystal violet mixture was carefully 
removed and rinsed with tap water. Plates with colonies were left to dry in normal air 
at room temperature (Franken et al., 2006). The density of colonies was identified by 
NTS Elements 4.0 imaging software (Nikon Inc., Melville, NY). Per cent colony 
formation was calculated by assigning untreated cultures as 100%. The present colony 
formation of treated cells was calculated by using the following formula:
 ^  ^ J 11 colony formation of treated cellspercent colony formation of treated cells = --------   x\ 00
colony formation of untreated cells
Flow Cytometry Analysis Using PE Annexin V Apoptosis Detection Kit I
PE Annexin V staining was used to identify apoptosis, and 7-Amino- 
actinomycin (7-AAD) was used to distinguish viable cells from non-viable in A2780, 
SKOV-3, H I299 and DU-145 cell lines. The cells were grown in 6-well plates at a 
seeding density of 2.5 xlO^ cells / 2 ml RPMI medium per flask. After overnight 
incubation, cell density was 5 x 10 .^ The cells were treated with free paclitaxel and
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paclitaxel/CD-GLU complexes for 48 h. The cells were washed with PBS (pH 7.4) 
and then harvested with trypsin EDTA. RPMI was added to get cell suspension. The 
suspension was centrifuged and supernatant was removed. Cells were washed twice 
with cold PBS and then resuspended in IX  Binding Buffer. The 100 pi o f the solution 
was transferred to culture tube. 5 pi of PE Annexin V and 5 pi 7-Amino-Actinomycin 
(7-AAD) were added. The cells were gently vortexed and incubated for 15 min at 
25°C in the dark. 400 pi of binding buffer was added to each tube. Then, flow 
cytometry analysis was conducted.
Statistics
All the data were processed using Microsoft Excel 2010 software and 
expressed as mean ± standard error o f the mean (S.E.M.). Statistical analyses were 
performed using an unpaired, two tailed student t-test. The results were only 
considered statistically significant if  p < 0.05.
2.4. Results and Discussion
Numerous studies have been carried out to develop efficient drug delivery 
systems for cancer chemotherapy. These studies suggest that apart from nanoparticles 
and hydrogels, inclusion complexes o f cyclodextrins with drug molecules have 
potential applications in drug delivery (Tsai et al., 2011; Boztas and Guiseppi-Elie, 
2009). Host-guest complexation between cyclodextrins and a wide range o f guest 
molecules have been studied by various groups to create macromolecular networks 
(self-assemblies or inclusion complexes) for drug delivery applications (Hirayama
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and Uekama, 1999). In the present study, novel L-glutamic acid derivative of p- 
cyclodextrin (CD-Glu) was developed to improve solubility and bioavailability of 
paclitaxel. CD-Glu was synthesized by a one pot condensation reaction of the triazine 
derivative of p-cyclodextrin and L-Glutamic acid mono sodium salt hydrate under 
alkaline conditions and low temperature (4 °C). The average molecular weight of 
highly water soluble CD-Glu was determined as 1515 by the ESI-TOF-mass 
spectroscopy. The molecular weight indicates that there is no reaction between 
cyclodextrins.
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Figure 2.2. X  NMR spectrum of p-cyclodextrin triazine (A), L-Glutamic acid 
monosodium salt (B) and glutamic acid derivative of p-cyclodextrin (CD-Glu) (C).
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CD-GLU was successfully characterized with ^HNMR spectroscopy. The two 
broadened peaks at 3.6 and 4.0 ppm correspond to the protons in pyranose rings of 
cyclodextrin triazine (Figure 2.2-A and C). The peaks around 2.15 and 2.50 ppm are 
assigned to 3"^  ^ and 4^  ^ carbon (-CH2) of glutamic acid, respectively. The doublets at 
-3.85 is attributed to the proton on the 2"  ^carbon (-CH) of glutamic acid. (Figure 2.2- 
B and C). The location of these signals as expected due to deshielding by the -N H 2 
group and the -COOH group. Both groups can cause deshielding in the 2-3ppm 
range. After coupling L-glutamic acid with cyclodextrin triazine, -C H  peak on 
glutamic acid shifted from 3.85 to 3.73 ppm due to the bond formation between 
glutamic acid and cyclodextrin triazine.
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Figure 2.3. Phase solubility diagram of paclitaxel/CD-Glu complexes.
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The complexation behaviour of paclitaxel with CD-Glu was investigated by 
phase solubility studies. Phase-solubility diagrams were achieved by plotting the 
concentration of dissolved guest drug molecule on the vertical axis against the 
concentration of the CD-Glu on the horizontal axis. (Figure 2.3) The phase solubility 
diagram also gave information about the stability of complexes formed. The 
extremely low water solubility of paclitaxel was improved significantly by CD-Glu 
encapsulation. For instance, after complexation of the paclitaxel with a concentration 
o f 12% (w/v) of CD-Glu, solubility increased to 0.18 mg/ml, which is approximately 
530 times higher than the original value, 0.34 pg/ml. A linear relationship was 
determined between the dissolved guest concentration and the amount of host 
molecule, so the encapsulation between CD-Glu and paclitaxel in water/ethanol 
(50:50) solution can be assumed as the ÂL-type phase-solubility diagram which is 
consistent with 1:1 complexation stoichiometry. The strength of encapsulation of 
paclitaxel with CD-Glu in terms of stability constant (Kc), was found to be 150.5 M”\  
which indicates relatively strong interactions between the guest and host molecules 
and consequently greater stability for the final complex (Yadav et al., 2009). Thus the 
value of stability constants show that the complexes formed between paclitaxel and 
CD-Glu is considerably stable.
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Figure 2.4. Cytotoxic effect of paclitaxel alone and complexed with CD-Glu on 
A2780, SKOV-3, H I299, DU-145 and MCF-7 cell lines as assessed by the MTT 
method for 72 h. CD-Glu complexes of paelitaxel have an improved therapeutic effect 
on all cancer eell lines eompared to free paclitaxel. Values are means (n =3) ±SD.
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Figure 2.5. The IC50 values (50% of cell growth inhibition) of paclitaxel and 
paelitaxel/CD-Glu on MCF-7, DU-145, SKOV-3, A2780 and H1299 eell lines.
Cell viability (MTT) assays were performed to investigate the potential 
cytotoxic effects of paclitaxel and their complexes for A2780, SKOV-3, H I299, DU- 
145 and MCF-7 eell lines. Untreated cells served as eontrols. The ineubation of cell 
lines was terminated after 72 hours and colorimetric determination of cell viabilities 
were performed. In Figure 2.4, cell viability of free paclitaxel and paelitaxel/CD-Glu 
complexes with increasing concentrations of paclitaxel are compared. Paclitaxel/CD- 
Glu complexes inhibited cell proliferation on A2780, SKOV-3, H I299 and DU-145 
cell lines in a dose-dependent manner and statistically more effectively than free 
paclitaxel. CD-Glu alone did not show any effect on cell growth. In the case of human 
mammary adenocarcinoma MCF-7 cell line, viability of cancer cells were slightly 
less for paclitaxel/CD-than the one at the same concentration of free paclitaxel. The
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ICso of paclitaxel/CD-Glu was found to be between 4.5 nM and 89.9 nM, while that of 
free paclitaxel ranged from 5.2 nM to 111.7 nM in all cancer cell lines (Figure 2.5). 
This accounts for almost 37% reduction in the IC50 value with paclitaxel complexes. 
The MTT study shows that paclitaxel/CD-Glu complex was more effective in 
arresting cell growth as compared to the free paclitaxel. The results reveal a 
synergistic interaction between paclitaxel and CD-Glu in several cellular processes. 
CD-Glu also seemed vastly useful for effective internalization o f the hydrophobic 
drug. Development in cytotoxicity was correlated with enhanced intracellular and 
nuclear delivery of paclitaxel. CD-Glu enhances the cytotoxicity of paclitaxel robustly 
against all types of human cancer cell lines except MCF-7. MCF-7 cells proliferate as 
colonies and less than 10 nM of paclitaxel is enough to kill 80 % of the MCF-7 cells. 
That’s why CD-Glu complexes of paclitaxel could not induce stronger synergistic 
effect compared to the paclitaxel alone on MCF-7 cells.
Clonogenic assays (colony formation assays) of cells were performed to 
investigate the long-term anti-cancer efficacy of paclitaxel and its CD-Glu complexes 
(Figure 2.6). Cell lines selected for the colony formation assay included A2780, 
SKOV-3, H I299, DU-145 and MCF-7. Data from the colony formation assay 
confirmed our previous MTT assay results indicating that a significant improvement 
in the therapeutic efficacy of paclitaxel/CD-Glu complex compared to free paclitaxel. 
Paclitaxel/CD-Glu complex showed better therapeutic effect than free paclitaxel on 
A2780, SKOV-3 H1299 and DU-145 cell lines. Both free paclitaxel and complexed 
paclitaxel showed similar effect on MCF-7 cell line.
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Figure 2.6. (A) Representative images of eolony forming assays of paelitaxel (Pax) 
and paclitaxel/CD-Glu complexes. Cells (500) were seeded in culture dishes and after 
24 h treated with the indicated amounts of paclitaxel or paelitaxel/CD-Glu. Cells were 
allowed to grow for 11 days. (B) Colony densities were expressed as a per cent of the 
control cells. The results show the mean± SE values.
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Figure 2.7. CD-Glu complexation of paclitaxel mostly increases the number of 
apoptotie eells. Four different human cancer cells (A2780, SKOV-3, H I 299 and DU- 
145) were treated with CD-Glu, paclitaxel and paclitaxel/CD-Glu eomplexes for 48 h. 
Apoptotie cells were measured with PE Annexin V staining by using flow cytometry.
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Flow cytometry analysis of the apoptosis induced by paclitaxel was carried out 
by performing PE Annexin V and 7-AAD staining for A2780, SKOV-3, H I299 and 
DU-145 cell lines (Figure 2.7 and 2.8). MCF-7 cells were not used for flow cytometry 
analysis since they proliferate as colonies and prevent accurate analysis. PE Annexin 
V measures the loss of phospholipid asymmetry and the accumulation of 
phosphatidylserine to the outer leaflet o f the plasma membrane taking place early 
during apoptosis and it is used to quantitatively determine the percentage of cells 
within a population that are actively undergoing apoptosis. 7-AAD is a standard flow 
cytometric viability probe and used to distinguish viable from nonviable cells. Viable 
cells with intact membranes exclude 7-AAD, whereas the membranes o f dead and 
damaged cells are permeable to 7-AAD. Cells that stain positive for PE Annexin V 
show apoptosis and cells that stain positive for 7-AAD are already dead.
Quantitative apoptotie and necrotic activity analysis achieved by flow 
cytometry shows that the drug induces apoptosis in each cancer cell line studied. 
Paclitaxel therapy with CD-Glu encapsulation suppressed the growth o f each cell type 
even at lower doses and resulted in an increase in both apoptosis and necrosis. The 
apoptotie effects were even more prominent when the drugs administered with CD- 
Glu complexation, particularly in human lung and ovarian carcinoma cells. In 
addition, flow cytometry analysis revealed that CD-Glu complexation makes 
paclitaxel highly effective in inducing the cellular apoptosis and cell death. These 
results correlate with the cell viability and colony formation data to confirm that CD- 
Glu plays an important role for delivering the hydrophobic drug into the tumor cells.
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Figure 2.8. Average cell death was determined with 7-AAD staining by using flow 
cytometry. Four different human cancer eells (A2780, SKOV-3, H I299 and DU-145) 
were treated with CD-Glu, paclitaxel and paclitaxel/CD-Glu complexes for 48 h. 
Apoptotie cells were measured with 7-AAD staining by using flow cytometry, CD- 
Glu complexation of paclitaxel mostly inereases the number of dead cells.
In conelusion, the encapsulation behaviour of paclitaxel with CD-Glu was 
investigated in order to enhance the aqueous solubility and therapeutic activity of 
paclitaxel. For that purpose, novel water-soluble CD-Glu was synthesized by 
condensation of the p-cyclodextrin triazine derivative and L-glutamic acid 
monosodium. The encapsulated form of paclitaxel led to a remarkable increase in 
water-solubility compared to the non-encapsulated form. Our results consistently 
demonstrate that CD-Glu encapsulated paclitaxel is more cytotoxic to cancer cells
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than free paclitaxel, particularly for ovarian, lung and prostate cancer cells. The 
enhanced solubility, stability and bioactivity of paclitaxel after CD-Glu complexation 
make this delivery method a promising one for the treatment of various cancer types.
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3.1. Abstract
The use of cytotoxic Chemotherapic agents is the most common method for 
the treatment of metastatic cancers. Poor water solubility and low efficiency of 
chemotherapic agents are among the major hurdles of effective chemotherapy 
treatments. Cureumin and paclitaxel are well known ehemotherapie agents with poor 
water-solubility and undesired side-effects. In this study, a novel drug nano-carrier 
system was formulated by encapsulating curcumin and paclitaxel in poly(P- 
cyclodextrin triazine) (PCDT) for the therapy of four cancer models; ovarian, lung, 
prostate and breast eancer. Cell viability and colony formation assays revealed 
enhanced curcumin cytotoxicity upon complexation. Annexin V apoptotie studies 
showed that the PCDT complexation improved curcumin induced apoptosis in human 
ovarian cancer cell lines A2780 and SKOV-3, human nonsmall cell lung carcinoma 
cell line H I299, and human prostate cancer line DU-145, while no significant effect 
was observed with paclitaxel/PCDT complexation. Therapeutic effects of combining 
curcumin and paclitaxel were also investigated. A synergism was found between 
curcumin and paclitaxel, particularly when complexed with PCDT on A2780, SKOV- 
3 and H I299 cancer cell lines.
Curcumin
Triazine
Paclitaxel
PCDT
monomer
Triazine
PCD'l
monomer
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3.2. Introduction
One of the main problems of cancer therapy is the decreasing therapeutic 
efficacy and the increasing toxicity related with the nonspecific accumulation of 
therapeutic agents in the non-target cells. Most therapeutic anticancer drugs are highly 
toxic and poorly soluble in water due to their hydrophobicity which presents critical 
challenges for clinical applications. Chemotherapic agents are applied in combination 
in order to suppress toxic side effects as well as to increase therapeutic index of 
anticancer drugs. On the other hand, intravenous administration of these molecules 
with organic solvents or surfactants causes either aggregation or insufficient drug 
doses at the tumor site. Therefore, the design of novel delivery systems of therapeutic 
agents without organic solvents has gained significant interest (Bae et al., 2007; 
Khdair et al., 2010).
Curcumin [l,7-bis(4-hydroxy-3-methoxyphenyl)-l,6-heptadiene-3, 5-dione], a 
low-molecular-weight polyphenol is the major bioactive ingredient extracted from the 
rhizome of the plant Curcuma longa Linn (turmeric). Curcumin has extensive 
biological and pharmacological functions, such as antioxidant, anti-inflammatory, 
anticancer , antibacterial, antispasmodic and anticoagulant, without any major side 
effects (Tang et al., 2002; Yallapu et al., 2012). In particular, anticancer activities of 
curcumin have been demonstrated in various organs and cell models, including 
leukemias, lymphomas, multiple myeloma, brain cancer and melanoma as well as 
skin, cervix, breast, prostate, ovarian, lung, gastrointestinal tract, bladder, liver, 
pancreatic and colorectal epithelial cancers (Singh et al., 2010; Yallapu et al., 2011). 
In spite of the promising biological effects of curcumin at the preclinical and clinical 
levels, its therapeutic applications are restricted because of its extremely low aqueous
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solubility, slow dissolution rate, instability and poor bioavailability. Thus, the 
development of an oral curcumin formulation has been a challenge with various 
approaches having been proposed in recent years (Yadav et al., 2010). Numerous 
methods have been studied to enhance the systemic bioavailability and delivery of 
curcumin, such as co-administration with other agents like liposomes, polymer 
nanoparticles, nanoemulsions, nanocrystal dispersions, lipid nanoparticles, or the use 
of different delivery systems (Basnet and Skalko-Basnet, 2011; Paramera et al., 
2011).
Paclitaxel is one of the most vital anticancer compounds extracted from the 
bark of Taxus brevifolia (Wani et al., 1971). It is highly effective in the treatment of 
various types of cancers, especially ovarian and breast cancers. It has a unique 
mechanism of action as it promotes the polymerization of tubulin dimmers to form 
microtubules and which then stabilizes the microtubules by preventing their 
depolymerization (Panchagnula, 1998). Like curcumin, paclitaxel is very hydrophobic 
and thus its solubility in an aqueous medium is very poor. Owing to this limited 
solubility, it is presently formulated in a delivery vehicle composed of 1:1 blend of 
Cremophor EL (polyethoxylated castor oil) and ethanol, which is diluted in normal 
saline and dextrose solution (5%) before the intravenous administration. However, 
there are many side effects associated with the intravenous administration of the 
present formulation, for example hypersensitivity, neurotoxicity, mucosities, elevation 
o f liver function tests and alopecia. Therefore, current approaches to enhance the 
therapeutic potential of paclitaxel mainly focus on the development of new aqueous 
formulations for paclitaxel in order to eliminate Cremophor EL and overcome the 
associated problems. These approaches include the use of liposomes, micelles, 
nanocapsules, polymeric microspheres, prodrugs, and bioconjugation with different
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molelcules, e.g., albumin, etc. One of the approaches that has gained much attention 
recently for the improvement in solubility and stability o f the paclitaxel is the 
complexation of paclitaxel with cyclodextrins (CDs) (Singla et al., 2002).
Cyclodextrins (CDs) are oligosaccharides composed of six or more D-gluco- 
pyranose residues attached by a-1,4-linkages in a cyclic array. The encapsulation of 
guest molecules in CDs leads to a change in their physicochemical properties and can 
result in increased stability, solubility, bioavailability, and tolerability(Jarho et al., 
1996) as well as in the elimination of negative side-effects of drugs (Szejtli, 1998). In 
addition, the majority of drugs form 1:1 complexes with various CDs (Horvath et al., 
2008; Stella and Rajewski, 1997). The most current CDs contain six, seven, or eight 
glucose residues and are named a-CD, P-CD, and y-CD, respectively (Wenz, 2003).
The internal cavity, which is highly hydrophobic, can accommodate a wide 
range of guest molecules, ranging from polar compounds such as alcohols, acids, 
amines, and small inorganic anions to nonpolar compounds, such as aliphatic and 
aromatic hydrocarbons (Hapiot et al., 2006; Szejtli, 1998). However, the enhancement 
of the water-solubility and bioactivity of curcumin and paclitaxel by pristine CDs is 
known to be fairly limited (Sharma et al., 1995). Intriguingly, complexation of an 
anticancer molecule to a water-soluble polymer often improves its pharmacodynamics 
and pharmacokinetic properties. Thus, it might be necessary to functionalize CDs 
with other molecules to enhance the solubility and therapeutic efficiency of the 
hydrophobic drugs with CD encapsulation.
In this work, 1 report the combined delivery of curcumin and paclitaxel 
complexed with a new CD polymer carrier, poly(P-cyclodextrintriazine) (PCDT), 
(Figure 3.1). The PCDT has a high water-solubility and it is envisaged that it can help
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increase the solubility, stability of curcumin and paclitaxel as well as their bioactivity 
in various cancer cell lines upon complexation.
3.3. Materials and methods
Materials
Curcumin, paclitaxel and glutaraldehyde were purchased from Alfa Aesar 
(Heysham, Lancashire, UK). The triazine derivative of P-cyclodextrin was supplied 
from CTD Inc. (High Springs, FL). Acetone and ethanol were supplied from Sigma- 
Aldrich (St. Louis, MO). Crystal Violet, ACS, 90+% was from Alfa Aesar (Ward 
Hill, MA). Dimethyl sulfoxide (DMSG) was purchased from VWR (West Chester, 
PA). DMEM medium, RPMI 1640 medium and trypsin EDTA were from Cellgro 
(Manassas, VA) and PE Annexin V Apoptosis Detection Kit I was purchased from 
BD Pharmingen (San Diego, CA). All materials were used without further 
purification.
Synthesis of PoIy(P-cyclodextrmtriazine)
PCDT was synthesized through a one-step condensation polymerization. An 
aqueous 5% (w/v) solution (pH 11.3) of P-cyclodextrintriazine was
electromagnetically stirred for 2 h in an ice-water bath and then for 12 hours at room 
temperature. Polymerization was stopped by neutralization with an aqueous 
hydrochloride acid solution (0.1 M). The resulting solution was purified by 
ultrafiltration (UF-5 membrane, nominal molar mass exclusion limit of 5 kg moF^). 
The final solution was freeze dried at 50 °C and at 1 mbar after being frozen at 80 °C. 
After freeze drying, a white amorphous powder was obtained.
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PCDT was characterized with gel permeation chromatography (GPC), FT-IR 
and ^H-NMR spectroscopy. The molecular masses of polymers were determined by 
using a GPC (Waters 717 plus; USA) with corresponding columns (Waters 
Ultrahydrogel linear column, 7.8x300 mm). 100 pL polymer solution (0.1 wt%, in 0.1 
M NaN03 aqueous solution) was injected. The flow rate was maintained at 1 
mL/min. ^H-NMR spectroscopic analyses were performed with Varian 300 MHz 
superconducting NMR-Spectrometer with deuterated dimethyl sulfoxide (DMS0-d6) 
as the solvent at 22 °C. FT-IR spectroscopy was carried out with KBr disks using a 
Nicolet 6700 FT-IR spectrometer. The scanning range was 4000-400 cm'^ and the 
resolution was 1 cm '\
Complexation of Poly(P-cyclodextrmtriazme) with Curcumin
The inclusion complex of curcumin with PCDT was prepared by the freeze- 
drying method. 20 pmol of PCDT was dissolved in 1.6 mL of deionized water in a 
glass vial containing a magnetic bar. 10 pmol o f curcumin dissolved in 1 mL acetone 
was added to PCDT aqueous solution while stirring in the dark at room temperature. 
Final solution was stirred overnight and then acetone was evaporated. The solution 
was passed through a 0.45 pm Agilent poly(vinylidene fluoride) (PVDF) syringe- 
driven filter unit and the supernatant containing highly water-soluble PCDT/curcumin 
complex was freeze dried.
Complexation of Poly(p-cyclodextrintriazine) with Paclitaxel
10 mg of paclitaxel was dissolved in 12 ml of ethanol and 85 mg o f PCDT was 
dissolved in 12 mL of water. PCDT solution was added to paclitaxel solution. Final
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solution was stirred for 5 h at room temperature. After ethanol evaporation, the mixed 
solution was centrifuged to remove the uncomplexed paclitaxel. The supernatant was 
then frozen and lyophilized.
Quantification of curcumin and paclitaxel
The concentration of curcumin and paclitaxel in complexes were determined 
by HPLC, (Shimadzu Prominence with LC-20AD Pumps) consisting a photodiode 
array detector and C l8 column (Shimadzu VP-ODS 250x4.6). Curcumin was detected 
at 425 nm. The mobile phase consisted of acetonitrile:water:acetic acid (50:49:1 
v:v:v); the flow rate was 1.0 ml/min and the volume of injection was 10 pi (Paramera 
et al., 2011). Paclitaxel was monitored at 227 nm with a methanol:water (70:30 v:v) 
of mobile phase, 1 ml/min of flow rate and 35 °C of oven temperature. A 20 pi of 
paclitaxel was injected into the HPLC for analysis.
Phase Solubility Analysis
The phase solubilities of curcumin and paclitaxel were examined by the 
method reported by Higuchi and Connors (Higuchi and Connors, 1965). Different 
concentrations of PCDT solutions were prepared in distilled water and filled in 
bottles. Excess curcumin or paclitaxel was added to these solutions to attain 
saturation. Each bottle was capped and agitated for an appropriate time on a shaker at 
22±0.5°C. The samples were withdrawn from the vials and filtrated through a 0.45 
pm filter. The resulting clear solutions were diluted and analyzed by HPLC. All 
measurements were done in triplicate and the samples were protected from light. The 
phase solubility diagram was constructed by plotting concentrations of dissolved 
curcumin and paclitaxel against cyclodextrin concentration. In the case of the
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formation of a 1:1 inclusion complex, the stability constant Kc can be obtained from 
the slope and intercept 5*0 of the initial straight line portion of the diagram in terms of 
the equation described by Higuchi and Connors (1965):
' S„{[C Z)],-(S,-S„)} S„(l-slope,)
To find Kc using the equation above, the molar concentration of PCDT was 
calculated by taking the monomer unit as its molecular weight to convert the units of 
CD polymer concentration from % (w/v) to mol/1 (Li et al., 2004).
Cell Culture
Human mammary adenocarcinoma MCF-7 cells and human prostate 
carcinoma DU-145 cells were propagated in DMEM medium, and human ovarian 
cancer cell lines A2780and SKOV-3 as well as human nonsmall cell lung carcinoma 
cell line H I299 were maintained in RPMI 1640 in a 37°C humidified atmosphere 
containing 95% air and 5% CO2 . Both DMEM and RPMI-1640 media were 
supplemented with 10% FBS, 2 mM L-glutamine, ImM sodium pyruvate, 100 I.U./ml 
Penicillin and 100 pg/ml Streptomycin.
Cytotoxicity with Single and Combination Therapy
I have tested the cytotoxic activity of the as-prepared inclusion complex and 
the parent drugs using five different cancer cell lines A2780, SKOV-3, H1299, DU- 
145 and MCF-7. The cells were plated at 3000 cells/well into 96-well tissue culture 
plates (Coming Glass Inc., Coming, NY) and incubated at 37°C in a humidified 
atmosphere containing 5% C02. After a 24 h recovery, cells were either untreated or 
treated for 72 h with free dmg and the PCDT formulations containing graded
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concentrations of paclitaxel, curcumin and combination o f paclitaxel and curcumin. 
Subsequently, cells received no further treatment. The cytotoxicity was measured 
using the MTT (Tsoli et al., 2005) [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H- 
tetrazolium bromide] cell survival assay (colorimetric method), wherein a tétrazolium 
compound is reduced to a formazan compound by living cells. The cell viability was 
evaluated by measurement of the absorbance at 570 nm. Eight replicates were made 
for each test condition, and plates were incubated for 3 days. The IC50 values were 
defined as the concentration o f drug that produces 50% of cell growth inhibition.
Additionally, drug combination analysis o f paclitaxel and curcumin was 
performed according to Chou and Talalay multiple drug interaction analysis (Chou et 
al., 1994; Chou and Talalay, 1984) based on the calculation of combination indices 
(CIs) using the following equation
Cl = a/A+ b/B,
where a is the paclitaxel IC50 value (50% of cell growth inhibition) in combination 
with curcumin at concentration b, A is the paclitaxel IC50 without curcumin, and B is 
the curcumin IC50 in the absence o f paclitaxel. According to this equation. Cl values 
of <1 indicate synergism, the smaller the value the greater the degree o f synergy; Cl 
values equal to 1 indicate additive affect; and CIs values of >1 indicate antagonism. 
All Cl ratios reported in this paper are the mean values derived from at least three 
independent experiments.
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Colony Formation Assay
Colony Formation Assay of cells in vitro was performed for the five human 
cancer cell lines A2780, SKOV-3, H1299, DU-145 and MCF-7. The cancer cells were 
seeded into 6-well plates in triplicates at a density of 1,000 cells/well in 2 ml of 
medium containing 10% FBS and allowed 3 day to initiate the colonies. These cells 
were treated with 5, 10, 15 pM of curcumin or curcumin/PCDT and 1 ,4 ,8  nM of 
paclitaxel or paclitaxel/PCDT and incubated for 11 days in a 37°C humidified 
atmosphere containing 5% CO2. The plates were rinsed with PBS. A mixture o f 6.0% 
glutaraldehyde and 0.5% crystal violet was then added and left for at least 30 min. 
The glutaraldehyde crystal violet mixture was carefully removed and rinsed with tap 
water. Plates with colonies were left to dry in normal air at room temperature 
(Franken et al., 2006). The density of colonies was identified by NIS Elements 4.0 
imaging software (Nikon Inc., Melville, NY). Percent colony formation was 
calculated by assigning untreated cultures as 100%. The percent colony formation of 
treated cells was calculated by using the following formula:
 ^ , J 11 colony formation of treated cellspercent colony formation of treated cells = ---------------------------------------------- xlOO
colony formation of untreated cells
Flow Cytometry Analysis Using PE Annexin V Apoptosis Detection Kit I
PE Annexin V staining was used to identify apoptosis, and 7-Amino- 
actinomycin (7-AAD) was used to distinguish viable cells from non-viable in A2780, 
SKOV-3, H1299 and DU-145 cell lines. The cells were grown in 6-well plates at a 
seeding density of 2.5 xlO^ cells / 2 ml RPMI medium per flask. After overnight 
incubation, cell density was 5x10^. The cells were treated with paclitaxel, curcumin.
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combination of paclitaxel and curcumin, and with their PCDT complexes for 48 h. 
The cells were washed with PBS (pH 7.4) and then harvested with trypsin EDTA. 
RPMI was added to get cell suspension. The suspension was centrifuged and 
supernatant was removed. Cells were washed twice with cold PBS and then 
resuspended in IX  Binding Buffer. The 100 pi o f the solution was transferred to 
culture tube. 5 pi of PE Annexin V and 5 pi 7-Amino-Actinomycin (7-AAD) were 
added. The cells were gently vortexed and incubated for 15 min at 25°C in the dark. 
400 pi of binding buffer was added to each tube. Then, flow cytometry analysis was 
conducted.
Statistics
All the data were processed using Microsoft Excel 2010 software and 
expressed as mean ± standard error o f the mean (S.E.M.). Statistical analyses were 
performed using an unpaired, two tailed student t-test. The results were only 
considered statistically significant if  p < 0.05.
3.4. Results
Poly(P-cyclodextrin-triazine) (PCDT) presented in Figure 3.1 was synthesized 
by polycondensation of the p-cyclodextrin-triazine derivative with 69% yield. The 
product was a white solid soluble in water and DMSO. The molecular mass was 
found to be 25.7 kg moF^ by GPC measurement. The optimum reaction time of 12 h 
for the polymerization was obtained from a model reaction that was monitored by 
ultraviolet-visible spectroscopy.
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Figure 3.1. Structure of Poly(p-cyclodextrin-triazine) (PCDT).
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Figure 3.2. FT-IR speetra of p-cyclodextrin triazine (CD-TRI) and poly(P- 
cyclodextrin triazine) (PCDT) (KBr tablet) from 4000 to 400 cm"'.
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The IR spectra of the (3-eyclodextrintriazine and homopolymer of p- 
cyclodextrintriazine are shown in Figure 3.2. The broad band at 1574 cm‘  ^ of p- 
cyclodextrintriazine may be assigned to the C=N ring stretching vibration of triazine. 
In addition, the homopolymer of p-cyclodextrintriazine showed a broad band at 1638 
cm'^ which may be attributed to the effect of triazine under basic conditions. This 
band is indicative of the polycondensation reaction among the p-cyclodextrin 
derivatives (Choi and Geckeler, 2007).
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Figure 3.3. ^H-NMR spectra of P-cyclodextrin triazine (CD-TRI), and poly(P-eyclo- 
dextrin triazine) (PCDT) in d-DMSO.
The H-NMR spectra of Poly (p-cyclodextrintriazine) (PCDT) and p- 
cyclodextrintriazine derivative were also investigated (Figure 3.3). The resonance
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signals of PCDT and P-cyclodextrintriazine are similar due to same structure except a 
shoulder signal at 4.98 of PCDT.
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Figure 3.4. Phase solubility diagram of curcumin-PCDT and paclitaxel-PCDT 
complexes.
The complexation of curcumin and paclitaxel with PCDT, the type of phase 
solubility diagram and the stability constant of complexes formed were investigated 
by phase solubility studies. Phase-solubility diagrams were achieved by plotting the 
concentration of dissolved guest drug molecules on the vertical axis against the 
concentration of the PCDT on the horizontal axis (Figure 3.4). The low water 
solubility of both hydrophobic agents has been improved significantly by 
encapsulation with PCDT. For instance, after complexation of the curcumin with a 
concentration of 16% (w/v) of PCDT, solubility increased up to 35.5mg/l,
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approximately 3500 times higher than the original value which is about 0.01 mg/1 
(Khopde et ah, 2000). On the other hand, solubility of paclitaxel with PCDT 12% 
(w/v) complex is 941 times higher than free paclitaxel which is 0.34 mg/l(Sharma et 
ah, 1995). Thus, the linear relationship was determined between dissolved guest 
concentration and amount of host molecule. The strength of encapsulation of 
curcumin with PCDT in terms of stability constant (Kc), which was calculated by 
taking the CD repeating unit as its molecular weight, was found to be 1126 M ~\ and 
Kc of paclitaxel / PCDT complex was calculated as 250
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Figure 3.5. Cytotoxic effect of curcumin alone and complexed with PCDT on A2780, 
SKOV-3, H1299, DU-145 and MCF-7 cell lines as assessed by the MTT method for 
72 h. PCDT complexes of curcumin have an improved therapeutic effect on all cancer 
cell lines compared to free curcumin. Values are means (n =3) ±SD.
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Figure 3.6. Cytotoxic effect of paclitaxel alone and complexed with PCDT on A2780, 
SKOV-3, H1299, DU-145 and MCF-7 cell lines as assessed by the MTT method for 
72 h. Values are means (n =3) ±SD.
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Figure 3.7. Cytotoxic effect of free paelitaxel and free cureumin combined with 
paclitaxel/PCDT and curcumin/PCDT in eombination on A2780, SKOV-3, H1299, 
DU-145 and MCF-7 cell lines as assessed by the MTT method for 72 h. PCDT 
eomplexes of paclitaxel + curcumin have an improved therapeutic effect especially on 
ovarian cancer cell lines (A2780 and SKOV-3) eompared to free paelitaxel + 
eurcumin. Values are means (n =3) ±SD.
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Table 3.1. The IC50 values (50% of cell growth inhibition) of paclitaxel, curcumin, 
paclitaxel/PCDT and curcumin/PCDT alone and in combination on MCF-7, DU-145, 
SKOV-3, A2780 and H1299 cell lines.
A2780 SKOV-3 H1299 DU-145 MCF-7
Paclitaxel (nM) 53.0 ± 1.7 36.7 ±14.9 31.4 ±2.5 7.9 ±2.1 9.4 ±2 .7
Paclitaxel / PCDT (nM) 40.4 ±3 .4 33.2 ± 16.2 31 .0±1.2 8.0 ± 0 .8 8.9 ±1 .2
Curcumin (pM) 11.5 ±3 .2 12.6 ± 3 .0 15.3 ±3 .0 13.3 ± 1.6 13.3 ± 1.2
Curcumin / PCDT (jiM) 8.1 ±3.5 9.3 ± 1.0 14.2 ±1.1 9.7 ± 1 .4 9.9 ± 1.7
Paclitaxel (nM) 27.6 ±13.9 22.0 ± 13.7 15.8 ±9.3 7.0 ± 0.2 6.2 ± 1 .4
+ ± ± ± ± ±
Curcumin (pM) 5.0 5.0 5.0 5.0 5.0
Paclitaxel / PCDT (nM) 3.5 ± 2.0 8.0 ±2.1 10.5 ±3 .9 6.5 ± 1.0 4.5 ± 1.4
+ ± ± ± ± ±
Curcumin / PCDT (|iiM) 5.0 5.0 5.0 5.0 5.0
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Table 3.2. Paclitaxel and curcumin combination index (CI) against A2780, SKOV-3, 
H1299, DU-145 and MCF-7 cell lines.
Paclitaxel (nM) 
+
Curcumin (jiM)
Paclitaxel / PCDT (nM)
+
Curcumin / PCDT (pM)
Cl
Interaction
Type
Cl
Interaction
Type
A2780 1.0 Additive 0.70 Synergistic
SKOV-3 1.0 Additive 0.78 Synergistic
H1299 0.83 Synergistic 0.69 Synergistic
DU-145 1.3 Antagonistic 1.3 Antagonistic
MCF-7 1.0 Additive 1.0 Additive
Cell viability (MTT) assays were performed to investigate the potential 
cytotoxic effects of combining curcumin, paclitaxel and their complexes for A2780, 
SKOV-3, H1299, DU-145 and MCF-7 cell lines. Untreated cells served as controls. 
The incubation of cells lines was terminated after 72 hours and colorimetric 
determination of cell viability was performed. In Figure 3.5, free curcumin and 
curcumin loaded PCDT complexes with increasing concentrations of curcumin are 
compared. Complexes inhibited cell proliferation in all five cell lines in a dose- 
dependent manner and statistically more effectively than free curcumin. The I C 5 0  of
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curcumin-PCDT was found to be between 8.1 pM to 14.2 pM, while that of free 
curcumin ranged from 11.5 pM to 15.3 pM among all the cancer cell lines (Table 
3.1). This accounts for almost 30% reduction in the I C 5 0  value with curcumin 
complexes. The MTT study shows that curcumin/PCDT were more effective in 
arresting cell growth as compared to that presented by free curcumin.
MTT assays were also performed using equivalent dosages of free paclitaxel, 
blank PCDT and paclitaxel/PCDT for 72 hours (Figure 3.6). Both paclitaxel and its 
complexes have shown dose dependant cytotoxic effects while PCDT did not show 
any effects on cell growth. Slightly less viable cancer cells were observed for 
paclitaxel/PCDT in comparison to the one observed at the same concentration of 
paclitaxel.
Finally, to investigate synergism I tested the potential cytotoxicity 
combination of curcumin (5 pM) with various concentrations of paclitaxel with or 
without encapsulation in PCDT (Figure 3.7). Notably, the IC50 values o f paclitaxel in 
cancer cell lines decreased significantly by the addition of 5 pM curcumin. I evaluated 
synergistic interaction according to Chou and Talalay multiple drug interaction 
analysis and combination index (Cl) values presented in Table 3.2. More synergistic 
inhibition was found between curcumin and paclitaxel, especially when complexed 
with PCDT for the human ovarian cancer cell lines (A2780 and SKOV-3) as well as 
human nonsmall cell lung carcinoma cell line (H I299).
93
(A)
A2780
Cur/
Cur
PCDT
Control
5 nM
10 fiM
15 mM
SKOV-3
Cur/ 
PCDTCur
H1299
Cur/
Cur PCDT
DU-145
Cur/
Cur
PCDT
MCF-7
Cur/
PCDT
m
f
^  80
60
5 10
Curcumin (|.iM)
■ A2780
■ SKOV-3
■ H1299
■ DU-145
■ MCF-7
5 10 15
Curcuniin/PCDT( plVI)
(C)
A2780
Pax/
Pax
Control
1 nM
4 nM
7n M
PCDT
SKOV-3
Pax/
Pax PCDT
H1299
Pax/
Fax PCDT
m m }
3
y
DU-145
Pax/
Pax PCDT
M CF-7
Pax/
Pax PCDT
94
(D)
100  -
1 4
Paclitaxel (nM)
A2780
SKOV-3
H 299
DU-145
MCF-7
1 4 8
Paclitaxel/PCDT (nM)
Figure 3.8. (A) Representative images of colony forming assays curcumin (Cur) and 
curcumin/PCDT complexes. (C) Representative images of colony forming assays 
paclitaxel (Pax) and paclitaxel/PCDT complexes. Cells (500) were seeded in culture 
dishes and after 24 h treated with the indicated amounts of curcumin or 
curcumin/PCDT. Cells were allowed to grow for 11 days. (B), (D) Colony densities 
were expressed as a percent of the control cells. The results show the mean± SE 
values.
Clonogenic assays (colony formation assays) of cells were performed to 
investigate long-term anti-cancer efficacy of parent drugs and their PCDT complexes. 
Cell lines selected for the colony formation assay included A2780, SKOV-3, H I299, 
DU-145 and MCF-7. Data from the colony formation assay confirmed our previous 
results, indicating that a significant improvement in the therapeutic efficacy of 
curcumin/PCDT complex in all three cell lines compared to free curcumin. 
Paclitaxel/PCDT complex showed better therapeutic effect than free paclitaxel on 
A2780, SKOV-3 and MCF-7cell lines. Both free paclitaxel and complexed paelitaxel 
showed similar effect on H I299 and DU-145 cell lines (Figure 3.8).
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Figure 3.9. PCDT complexation mostly increases the number of apoptotic and dead 
cells. Four different human cancer cells (A2780, SKOV-3, H I299 and DU-145) were 
treated with curcumin (Cur) and paclitaxel (Pax) alone or in combination which are 
formulated in solution and PCDT encapsulation for 48 h. Apoptotic cells were 
measured with PE Annexin V staining and cell death was determined with 7-AAD 
staining by using flow cytometry.
Flow cytometry analysis of the apoptosis induced by curcumin and paclitaxel 
was carried out by performing PE Annexin V and 7-AAD staining for A2780, SKOV- 
3, H I299 and DU-145 cell lines. PE Annexin V measures the loss o f phospholipid 
asymmetry and the accumulation of phosphatidylserine to the outer leaflet o f the 
plasma membrane taking place early during apoptosis and it is used to quantitatively 
determine the percentage of cells within a population that are actively undergoing 
apoptosis. 7-AAD is a standard flow cytometric viability probe and is used to 
distinguish viable from nonviable cells. Viable cells with intact membranes exclude 7- 
AAD, whereas the membranes of dead and damaged cells are permeable to 7-AAD. 
Cells that stain positive for PE Annexin V show apoptosis and cells that stain positive 
for 7-AAD are already dead (Figure 3.9).
3.5. Discussion
Cancer cells avoid apoptosis as a result o f downregulation o f apoptotic 
proteins and upregulation of antiapoptotic proteins. Expression of growth signalling 
pathways tolerates them to defend against therapy induced apoptosis. Curcumin 
interferes with cancer cell growth by means of the inhibition of NFkB (nuclear factor-
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kappa B) activity occurring through the downregulation of IKKp (IkB kinase P) and 
potentiate tumor cell response to different NFkB activating anticancer drugs like 
paclitaxel (Duarte et ah, 2010). Recent studies suggest that curcumin can enhance the 
cytotoxicity of some other anticancer molecules against various cancer types. 
Moreover, some in vitro studies demonstrated synergism between curcumin and 
paclitaxel. For instance, curcumin potentiates effects of paclitaxel against HeLa cells 
and augments it to suppress the metastasis of human breast cancer to the lungs in nude 
mice (Tsai et al., 2011).
Numerous studies have been carried out to develop efficient drug delivery 
systems for cancer chemotherapy. These studies suggest that apart firom nanoparticles 
and hydrogels, inclusion complexes of polymers with drug molecules have potential 
applications in drug delivery (Boztas and Guiseppi-Elie, 2009; Elirayama and 
Uekama, 1999). For a formulation of a polymeric drug delivery carrier to be 
successful it must be capable of encapsulating or loading the desired amounts o f drug 
within its structure and deliver them in active form to the cancerous tissues. Host- 
guest complexation between cyclodextrins and a wide range of guest molecules have 
been employed by various groups to create macromolecular networks (self-assemblies 
or inclusion complexes) for drug delivery applications (Yallapu et al., 2010).
In the present study, a triazine conjugated cyclodextrin polymer (PCDT) was 
developed to improve solubility and bioavailability of curcumin and paclitaxel. The 
phase-solubility investigations were performed in aqueous media and used to examine 
complex stoichiometry and the relative affinity o f both hydrophobic agents for PCDT. 
The linear relationship was determined between dissolved guest concentration and 
amount of host molecule. (Figure 3.5) The formation of an encapsulation between the 
soluble polymer PCDT and both drugs in aqueous solution can be assumed as the A l-
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type phase-solubility diagram which is consistent with 1:1 complexation 
stoichiometry. Accordingly, each CD monomer of PCDT encapsulates either one 
curcumin or paclitaxel molecule. The strength of encapsulation of curcumin with 
PCDT in terms of stability constant (Kc), which was calculated by taking the CD 
repeating unit as its molecular weight, was found to be 1126 ]V r\ which is higher than 
the stability constant of pCD (134 M~^) and HPpCD (424 M~^) (Yadav et al., 2009). 
And stability constant of paclitaxel / PCDT complex was calculated as 250 Kc 
values in the range of 200-5000 M'^ indicate strong interactions between the guest and 
host molecules and consequently greater stability for the final complex (Patel and 
Patel, 2007). Thus the values of stability constants show that the complexes formed 
between both drugs and PCDT is considerably stable.
The effect of both hydrophobic drugs alone and in combination with PCDT 
complexation therapy on growth of A2780, SKOV-3, H1299, DU-145 and MCF-7 
cells were studied (Table 3.1 and Table 3.2). The results reveal an interaction between 
curcumin and paclitaxel in several cellular processes. PCDT also seemed vastly useful 
for effective internalization of both drugs. Development in cytotoxicity was correlated 
with enhanced intracellular and nuclear delivery of the two drugs. The results show 
that curcumin enhances the cytotoxicity of paclitaxel against five different types o f 
human cancer cells.
Quantitative apoptotic and necrotic activity analysis were achieved by flow 
cytometry in curcumin and paclitaxel treated cells. Analysis shows that both drugs 
induce apoptosis in each cancer cell studied. The results are very significant because it 
shows both the synergistic effect of curcumin and paclitaxel with or without PCDT 
encapsulation. Combination therapy with PCDT encapsulation suppressed the growth 
of each cell type even at lower doses and resulted in a significant induction o f both
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apoptosis and necrosis. The apoptotic effects were even more prominent when the 
drugs administered with PCDT complexation particularly in human lung and ovarian 
carcinoma cells. In addition to these observations, flow cytometry analysis revealed 
that PCDT complexation makes curcumin highly effective in inducing the cellular 
apoptosis and cell death. These results correlate with the cell viability and colony 
formation data to confirm that PCDT plays an important role for delivering the 
hydrophobic drugs alone and in combination into the tumor cells.
In conclusion, hydrophobic anticancer drugs, curcumin and paclitaxel, were 
successfully encapsulated into PCDT and delivered into human cancer cells to induce 
apoptosis. Our results consistently demonstrate that encapsulated curcumin is more 
cytotoxic to cancer cells than free curcumin. On the other hand, encapsulation in 
PCDT did not change cytotoxicity of paclitaxel significantly, which urges further 
studies on different encapsulation approaches. Curcumin alone increases free 
paclitaxel’s cytotoxicity synergistically only for H I299 cell line. Further, I 
demonstrated a highly synergistic interaction between curcumin and paclitaxel 
complexed with PCDT in two human ovarian carcinoma cells and a human nonsmall 
cell lung carcinoma cell. This synergistic therapeutic method with PCDT 
encapsulation offers considerable potential in the clinical trials for ovarian and lung 
cancers.
100
3.6. References
Bae, Y., Diezi, T.A., Zhao, A., and Kwon, G.S. (2007). Mixed polymeric 
micelles for combination cancer chemotherapy through the concurrent delivery of 
multiple chemotherapeutic agents. Journal of Controlled Release 122, 324-330.
Basnet, P., and Skalko-Basnet, N. (2011). Curcumin: an anti-inflammatory 
molecule from a curry spice on the path to cancer treatment. Molecules 16, 4567- 
4598.
Boztas, A.O., and Guiseppi-Elie, A. (2009). Immobilization and release of the 
redox mediator ferrocene monocarboxylic acid from within cross-linked p (HEMA- 
co-PEGMA-co-HMMA) hydrogels. Biomacromolecules 70, 2135-2143.
Choi, S., and Geckeler, K. (2007). A novel polycondensate containing 
cyclodextrin and lactose: Synthesis, metal-complexing properties, and degradation. 
Polymer 45, 1445-1449.
Chou, T.C., Motzer, R.J., Tong, Y., and Bosl, G.J. (1994). Computerized 
quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against 
human teratocarcinoma cell growth: a rational approach to clinical protocol design. 
Journal of the National Cancer Institute 86, 1517-1524.
Chou, T.C., and Talalay, P. (1984). Quantitative analysis of dose-effect 
relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances 
in enzyme regulation 22, 27-55.
101
Duarte, V.M., Han, E., Veena, M.S., Salvado, A., Suh, J.D., Liang, L.J., Faull, 
K.F., Srivatsan, E.S., and Wang, M.B. (2010). Curcumin enhances the effect of 
cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of 
IKKp protein of the NFkB pathway. Molecular cancer therapeutics P, 2665-2675.
Franken, N.A.P., Rodermond, H.M., Stap, J., Haveman, J., and Van Bree, C. 
(2006). Clonogenic assay o f cells in vitro. Nature protocols 7, 2315-2319.
Hapiot, F., Tilloy, S., and Monflier, E. (2006). Cyclodextrins as
supramolecular hosts for organometallic complexes. Chemlnform 37, no-no.
Higuchi, T., and Connors, K.A. (1965). Phase-solubility techniques. Adv. 
Anal. Chem. Instrum 4, 117-212.
Hirayama, F., and Uekama, K. (1999). Cyclodextrin-based controlled drug 
release system. Advanced drug delivery reviews 36, 125-141.
Horvath, G., Premkumar, T., Boztas, A., Lee, E., Jon, S., and Geckeler, K.E. 
(2008). Supramolecular Nanoencapsulation as a Tool: Solubilization of the
Anticancer Drug trans-Dichloro (dipyridine) platinum (11) by Complexation with p- 
Cyclodextrin. Molecular Pharmaceutics 5, 358-363.
Jarho, P., Urtti, A., Jarvinen, K., Pate, D.W., and Jarvinen, T. (1996). 
Hydroxypropyl-P-cyclodextrin increases aqueous solubility and stability o f
anandamide. Life sciences 58, 181-185.
Khdair, A., Patil, Y., Ma, L., Dou, Q.P., Shekhar, M.P.V., and Panyam, J. 
(2010). Nanoparticle-mediated combination chemotherapy and photodynamic therapy 
overcomes tumor drug resistance. Journal o f Controlled Release 141, 137-144.
102
Khopde, S.M., Indira Priyadarsini, K., and Mukherjee, T. (2000). Effect of 
Solvent on the Excited-state Photophysical Properties of Curcumin. Photochemistry 
and photobiology 72, 625-631.
Li, J., Xiao, H., Li, J., and Zhong, Y.P. (2004). Drug carrier systems based on 
water-soluble cationic P-cyclodextrin polymers. International journal of 
pharmaceutics 278, 329-342.
Panchagnula, R. (1998). Pharmaceutical aspects of paclitaxel. International 
journal of pharmaceutics 172, 1-15.
Paramera, E.I., Konteles, S.J., and Karathanos, V.T. (2011). Stability and 
release properties of curcumin encapsulated in< i> Saccharomyces cerevisiae</i>, P- 
cyclodextrin and modified starch. Food Chemistry 125, 913-922.
Patel, R., and Patel, M. (2007). Preparation and Evaluation o f Inclusion 
Complex o f the Lipid Lowering Drug Lovastatin with?-Cyclodextrin. Dhaka 
University Journal o f Pharmaceutical Sciences 6, 25-36.
Sharma, U.S., Balasubramanian, S.V., and Straubinger, R.M. (1995). 
Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with 
cyclodextrins. Journal of pharmaceutical sciences 8 4 ,1223-1230.
Singh, R., Tonnesen, H.H., Vogensen, S.B., Loftsson, T., and Masson, M.
(2010). Studies of curcumin and curcuminoids. XXXVl. The stoichiometry and 
complexation constants of cyclodextrin complexes as determined by the phase- 
solubility method and UV-Vis titration. Journal of Inclusion Phenomena and 
Macrocyclic Chemistry 66, 335-348.
103
Singla, A.K., Garg, A., and Aggarwal, D. (2002). Paclitaxel and its 
formulations. International journal of pharmaceutics 235, 179-192.
Stella, V.J., and Rajewski, R.A. (1997). Cyclodextrins: their future in drug 
formulation and delivery. Pharmaceutical research 14, 556-567.
Szejtli, J. (1998). Introduction and general overview o f cyclodextrin 
chemistry. Chemlnform 29, no-no.
Tang, B., Ma, L., Wang, H.Y., and Zhang, G. (2002). Study on the 
supramolecular interaction of curcumin and P-cyclodextrin by spectrophotometry and 
its analytical application. Journal of agricultural and food chemistry 50, 1355-1361.
Tsai, M.S., Weng, S.H., Kuo, Y.H., Chiu, Y.F., and Lin, Y.W. (2011). 
Synergistic effect o f curcumin and cisplatin via down-regulation of thymidine 
phosphorylase and excision repair cross-complementary 1 (ERCCl). Molecular 
pharmacology 50, 136-146.
Tsoli, M., Kuhn, H., Brandau, W., Esche, H., and Schmid, G. (2005). Cellular 
uptake and toxicity of Au55 clusters. Small 1, 841-844.
Wani, M.C., Taylor, H.L., Wall, M.E., Coggon, P., and McPhail, A.T. (1971). 
Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and 
antitumor agent from Taxus brevifolia. Journal of the American Chemical Society 93, 
2325-2327.
Wenz, G. (2003). Cyclodextrins as building blocks for supramolecular 
structures and functional units. Angewandte Chemie International Edition in English 
35, 803-822.
104
Yadav, V.R., Prasad, S., Kannappan, R., Ravindran, J., Chaturvedi, M.M., 
Vaahtera, L., Parkkinen, J., and Aggarwal, B.B. (2010). Cyclodextrin-complexed 
curcumin exhibits anti-inflammatory and antiproliferative activities superior to those 
of curcumin through higher cellular uptake. Biochemical pharmacology 80, 1021- 
1032.
Yadav, V.R., Suresh, S., Devi, K., and Yadav, S. (2009). Effect of 
cyclodextrin complexation o f curcumin on its solubility and antiangiogenic and anti­
inflammatory activity in rat colitis model. AAPS PharmSciTech 10, 752-762.
Yallapu, M.M., Ebeling, M.C., Chauhan, N., Jaggi, M., and Chauhan, S.C.
(2011). Interaction of curcumin nanoformulations with human plasma proteins and 
erythrocytes. International journal of nanomedicine 6, 2779.
Yallapu, M.M., Jaggi, M., and Chauhan, S.C. (2010). Poly (P- 
cyclodextrin)/Curcumin Self-Assembly: A Novel Approach to Improve Curcumin 
Delivery and its Therapeutic Efficacy in Prostate Cancer Cells. Macromolecular 
bioscience 10, 1141-1151.
Yallapu, M.M., Jaggi, M., and Chauhan, S.C. (2012). Curcumin 
nanoformulations: a future nanomedicine for cancer. Drug discovery today 77, 71-80.
105
Chapter 4
Conjoint Antitumor Effects of Cisplatin 
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Poloxamer Formulation
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4.1. Abstract
Hydrogels are commonly used for the delivery of drugs to protect them from 
degradation, improve their bioavailability and facilitate local delivery. In this study, a 
novel oleic acid coupled poloxamer (POA) hydrogel is synthesized to enhance 
chemotherapeutic effects of cancer therapy agents, curcumin (CUR) and cisplatin 
(CPT). Therapeutic effects of CUR and CPT combinations were investigated in three 
cancer models; ovarian, lung and prostate cancer. Cell viability and colony formation 
assays revealed that amphiphilic and thermosensitive POA hydrogel robustly 
enhances the cytotoxicity of CPT. In addition, a synergism was determined between 
CPT and CUR, in particular when formulated with POA on human ovarian cancer cell 
line A2780 and human nonsmall cell lung carcinoma cell line H I299. Furthermore, 
analysis of apoptosis by Annexin V showed that POA inereases CPT and CUR 
induced apoptosis in A2780 and H I299 cell lines. This study demonstrates that 
administration of CPT-POA and CUR-POA formulations conjointly leads to 
synergistic improvement in the efficiency of chemotherapy as evidenced by higher 
number of apoptotic cells and decreased colony formation by various cancer models.
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4.2. Introduction
Most therapeutic anticancer drugs are poorly soluble in water and demonstrate 
high toxicity. These factors severely limit their bioavailability and create problems for 
their clinical applications (Kamaly et al., 2012). As such, one of the main challenges 
of cancer therapy is increasing the therapeutic efficacy while lowering the toxicity 
related with the nonspecific accumulation of therapeutic agents in the non-target cells. 
Often chemotherapic agents are given to the body in combination with other organic 
solvents or surfactants in order to suppress their toxic side effects as well as to 
increase their therapeutic index. On the other hand, intravenous administration of 
these molecules with organic solvents or surfactants causes either aggregation or 
insufficient drug doses at the tumor site. Therefore, developing novel delivery 
systems of therapeutic agents without organic solvents has gained significant attention 
(Bae et ah, 2007).
CPT (cw-diamminedichloroplatinum(II)) has been widely used as a 
chemotherapeutic agent for the treatment of various types of cancer. It covalently 
binds DNA and interfere DNA replication and eventually triggers apoptosis (Ali et ah, 
2013). However, the efficacy of this chemotherapeutic drug is hampered by drug 
resistance in the advanced stages of cancer and can be enhanced when used with 
radiation therapy or in combination with other chemotherapeutic drugs (Florea and 
Biisselberg, 2011).
CUR [ 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3, 5-dione], has 
extensive biological and pharmacological functions, such as antioxidant, anticancer , 
antibacterial, without major side effects (Yallapu et ah, 2012a). Anticancer activity of 
CUR has been demonstrated in various organs and cell models (Yallapu et ah, 2011).
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CUR interferes with cancer cell growth by inhibiting the NFkB activity which occurs 
through the downregulation of IKXp and potentiate tumor cell response to different 
NFkB activating anticancer drugs (Duarte et ah, 2010). Recent studies suggest that 
CUR can enhance the cytotoxicity of some other anticancer molecules against various 
cancer types. In spite of the promising biological effects o f CUR at the preclinical and 
clinical levels, its therapeutic applications are limited because o f its extremely low 
aqueous solubility, slow dissolution rate, instability and poor bioavailability. Thus, the 
development of an oral CUR formulation has been a challenge with various 
approaches having been proposed in recent years (Yadav et ah, 2010). Numerous 
methods have been studied to enhance the systemic bioavailability and delivery of 
CUR (Basnet and Skalko-Basnet, 2011). One possible way is to encapsulate the drug 
into polymeric micellar nanocarriers. These polymeric micellar nanocarriers have 
shown potential as drug nanocarriers against various diseases and oral delivery of 
therapeutic drugs (Bae et ah, 2007; Guo et ah, 2007; Sahu et ah, 2011).
Polymeric micelles made of Pluronic block copolymers (poloxamer) are 
biocompatible and promising candidates for effectively carrying hydrophobic drugs. 
Poloxamer is approved by US FDA for pharmaceutical and medical applications 
(Bonacucina et ah, 2011). Poloxamer is composed of hydrophilic ethylene oxide (EO) 
and hydrophobic propylene oxide (PC) blocks, arranged in a tri-block structure of 
EOa-POb-EOa (PEO-PPO-PEO) where a and b chain lengths vary from 2-130 and 
16-70 units, respectively. This structure results in amphiphilic copolymers that self- 
assemble into spherical micelles in aqueous solutions above critical gelation 
temperature and concentration (Hatefi and Amsden, 2002). The core is formed by the 
hydrophobic interaction of the PO block and stays separated from the aqueous 
exterior by the hydrophilic corona formed by EO blocks. This physically cross-linked
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gel structure has been widely used as a drug delivery carrier because it shows 
exceptional sol-gel transition behaviour in response to temperature in aqueous 
solution (Leroux and Ruel-garie, 2004). The hydrophobic core of such micelles 
functions as a cargo space for carrying non-polar therapeutic compounds, while the 
hydrophilic corona enhances the pharmaceutical behaviour of block copolymer. The 
non-covalent incorporation of drugs with the hydrophobic PO core o f the Pluronic 
micelles results in increased solubility, metabolic stability, bioavailability, and 
circulation time. In addition, Pluronic block copolymers have demonstrated enhanced 
therapeutic activity of many chemotherapeutic agents such as paclitaxel, and CPT 
(Exner et al., 2005; Guo et al., 2007, 2009).
Recently, oleic acid has attracted great deal of attention due to its anti-cancer 
effect (Carrillo and Cavia, 2012). A number o f studies demonstrated potential effects 
o f olive oil and oleic acid against breast cancer and colorectal cancer (Mar et al., 
2001)’(Stoneham et al., 2000). Moreover, animal studies have shown that dietary olive 
oil prevents colon carcinomas in rats (Bartoli et al., 2000). It was also reported that 
oleic acid acts synergistically with chemotherapeutic agents and improve their 
antitumor effect.
In this study, I report a thermo-sensitive oleic acid-coupled poloxamer (POA) 
hydrogel as a carrier for chemotherapic drugs CUR and CPT. Oleic acid coupled to 
poloxamer (Pluronic F 127) was synthesized through ester linkage between the 
carboxyl group of oleic acid and hydroxyl group of poloxamer without catalyst or 
solvent. I hypothesized that the incorporation of CUR and CPT in to OA-coupled 
Poloxamer would increase their solubility and stability, thus resulting in increased 
efficacy and reduced drug resistance. The therapeutic effects of the incorporation of
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hydrophobic CUR and hydrophilic OPT with OA-coupled poloxamer were assessed in 
three different cancer types; ovarian, lung and prostate.
4.3. Materials and methods
Materials
CPT, 99% was supplied from TSZ Chem (Albuquerque, NM). CUR and 
glutaraldehyde were purchased from Alfa Aesar (Heysham, Lancashire, UK). 
Poloxamer (Pluronic® F-127) was from Sigma-Aldrich (St. Louis, MO). Oleic acid, 
90%, diethyl ether, 99 % and crystal violet, ACS, 90+% were supplied from Alfa 
Aesar (Ward Hill, MA). Dimethyl sulfoxide and dimethylformamide were purchased 
from VWR (West Chester, PA). DMEM medium, RPMI 1640 medium and trypsin 
EDTA were from Cellgro (Manassas, VA) and PE Annexin V Apoptosis Detection 
Kit I was purchased from BD Pharmingen (San Diego, CA).
Synthesis of oleic acid-coupled poloxamer
Oleic acid coupled poloxamer (POA) was prepared at the melting phase 
without catalyst or solvent through ester linkages between the carboxyl group of oleic 
acid and the hydroxyl group of poloxamer as described previously (Guo et al., 2009). 
Oleic acid (44.5 mmol) and poloxamer (1 mmol) were added into a round bottom 
flask and the mixture was heated with continuous stirring to produce a well-mixed 
molten phase and reacted at 150 °C for 5 h under the nitrogen as shown in reaction 
scheme (Figure 4.1 A ) . The POA was obtained by dropping the resulting solution into 
ethyl ether to remove the unreacted oleic acid. Finally, the precipitated POA was 
vacuum dried to constant weight at room temperature overnight. The purified POA
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was characterized with ^H-NMR spectroscopy (Varian 300 MHz superconducting 
NMR-Spectrometry in CDCI3).
Solubility studies
The solubility of the CUR in POA hydrogel solutions was examined by adding 
excess of the CUR to vials containing 1%, 3%,5% and 7% (w/v) POA solutions. The 
vials were sealed, and shaken for 4 h at 4 °C. The solution was filtered through a 0.45 
pm filter to remove all solid material and the concentration of dissolved CUR was 
determined by HPLC, (Shimadzu Prominence with LC-20AD Pumps) consisting a 
photodiode array detector and Cig column (Shimadzu VP-ODS 250x4.6). CUR was 
detected at 425 nm. The mobile phase consisted of acetonitrile:water:acetic acid 
(50:49:1 v:v:v); the flow rate was 1.0 ml/min and the volume of injection was 10 pi 
(Paramera et al., 2011).
Cell Culture
Human prostate carcinoma DU-145 cells were propagated in DMEM medium, 
and human ovarian cancer cell line A2780 as well as human nonsmall cell lung 
carcinoma cell line H I299 were maintained in RPMI 1640 in a 37°C humidified 
atmosphere containing 95% air and 5% CO2. Both DMEM and RPMI-1640 media 
were supplemented with 10% FBS, 2 mM L-glutamine, ImM sodium pyruvate, 100 
I.U./ml Penicillin and 100 pg/ml Streptomycin.
Cytotoxicity with Single and Combination Therapy
We have tested the cytotoxic activity of the anticancer drugs alone and their 
POA hydrogel formulations using three different cancer cell lines A2780, H I299 and
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DU-145. The cells were plated at 3000 cells/well into 96-well tissue culture plates 
(Coming Glass Inc., Coming, NY) and incubated at 37°C in a humidified atmosphere 
containing 5% CO2. After a 24 h recovery, cells were either untreated or treated for 72 
h with free dmg and drug - POA formulations containing graded concentrations of 
CPT, CUR and combination o f CPT and CUR. Subsequently, cells received no further 
treatment. The cytotoxicity was measured using the MTT(Tsoli et al., 2005) [3-(4,5- 
dimethyl-2-thiazolyl)-2,5-diphenyl-27/-tetrazolium bromide] cell survival assay 
(colorimetric method), wherein a tétrazolium compound is reduced to a formazan 
compound by living cells. The cell viability was evaluated by measurement o f the 
absorbance at 570 nm. Eight replicates were made for each test condition, and plates 
were incubated for 3 days. The I C 5 0  values were defined as the concentration of dmg 
that produces 50% of cell growth inhibition.
Additionally, dmg combination analysis of CPT and CUR was performed 
according to Chou and Talalay multiple dmg interaction analysis (Chou and Talalay, 
1984) based on the calculation of combination indices (CIs) using the following 
equation:
Cl = a!A-\- bIB,
where a is the CPT IC50 values (50% of cell growth inhibition) in combination with 
CUR at concentration b, A is the CPT IC50 without CUR, and B is the CUR IC50 in the 
absence of CPT. According to this equation. Cl values of <1 indicate synergism, the 
smaller the value the greater the degree of synergy; Cl values equal to 1 indicate 
additive affect; and CIs >1 indicate antagonism. Each Cl ratio reported in this paper is 
the mean value derived from at least three independent experiments.
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Colony Formation Assay
Colony Formation Assay of cells in vitro was performed for the two human 
cancer cell lines which are A2780 and H I299. The cancer cells were seeded into 6- 
well plates in triplicates at a density of 1,000 cells/well in 2 ml of medium containing 
10% FBS and allowed 3 day to initiate the colonies. These cells were treated with 0.5, 
2 and 5 pM of CPT or CPT/POA and 5, 10, 15 pM of CUR or CUR/POA. All treated 
cells were incubated for 11 days in a 37°C humidified atmosphere containing 5% 
CO2. The plates were rinsed with PBS. A mixture of 6.0% glutaraldehyde and 0.5% 
crystal violet was then added and left for at least 30 min. The glutaraldehyde crystal 
violet mixture was carefully removed and rinsed with tap water. Plates with colonies 
were left to dry in normal air at room temperature (Franken et al., 2006). The density 
of colonies was identified by NIS Elements 4.0 imaging software (Nikon Inc., 
Melville, NY). Percent colony formation was calculated by assigning untreated 
cultures as 100%. The percent colony formation of treated cells was calculated by 
using the following formula:
 ^ . j  11 colony formation of treated cellspercent colony formation of treated cells = --------   xlOO
colony formation o f untreated cells
Flow Cytometry Analysis Using PE Annexin V Apoptosis Detection Kit I
PE Annexin V staining was used to identify apoptosis, and 7-Amino- 
actinomycin (7-AAD) was used to distinguish viable cells from non-viable in human 
ovarian cancer cell line A2780 and human nonsmall cell lung carcinoma cell line 
H1299. The cells were grown in 6-well plates at a seeding density of 2.5 xlO^ cells / 2 
ml RPMI medium per flask. After overnight incubation, cell density increased to 5 x
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10 .^ The cells were treated with CPT, CUR, combination of CPT and CUR, and their 
hydrogel formulations for 48 h. The cells were washed with PBS (pH 7.4) and then 
harvested with trypsin EDTA. RPMI was added to get cell suspension. The 
suspension was centrifuged and supernatant was removed. Cells were washed twice 
with cold PBS and then resuspended in IX  Binding Buffer. The 100 pi of the solution 
was transferred to culture tube. 5 pi of PE Annexin V and 5 pi 7-Amino-Actinomycin 
(7-AAD) were added. The cells were gently vortexed and incubated for 15 min at 
25°C in the dark. 400 pi of binding buffer was added to each tube. Then flow 
cytometry analysis was conducted.
Statistics
All the data were processed using Microsoft Excel 2010 software and 
expressed as mean ± standard error of the mean (S.E.M.). Statistical analyses were 
performed using an unpaired, two tailed student t-test. The results were only 
considered statistically significant if  p < 0.05.
4.4. Results 
Characterization of POA
The NMR spectrum of POA is shown in Figure 4 .IB. The peaks at 5.2-5.4 
ppm (1) were assigned to the protons of double bonds of OA. No oxidation o f the 
double bond of OA was observed indicating successful synthesis of POA. The peaks 
at 3.2-3.8 ppm (2) were assigned to the protons of [-C H 2-C H 2-0-] and [-C H 2-C H - 
0 - ]  groups. The peaks at 1.1 ppm (3) were assigned to protons of [-CH3] group. The 
composition of OA in the synthesized OA-coupled poloxamer estimated by ^H NMR
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spectroscopy was 58 mol %. The reported chemical structure for the Pluronic F I27 is 
PEO 100, PP065, P E O 100 (Figure 4.1.A) and its nominal molar mass is
12,600 gmol -1
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Figure 4.1. (A) Synthesis of POA by the reaction of oleic acid and poloxamer. (B) H 
NMR spectrum of POA in C D C I 3 .
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Solubility of CUR in POA Hydrogel
Solubility of CUR was studied in 1, 3, 5, and 7% POA hydrogel by HPLC 
(Figure 4.2). The extremely low water solubility of both CUR has been improved 
significantly in POA. For instance, solubility of the CUR with the 7% POA increased 
up to 0.5 mg/ml which is almost 5000 times of pure CUR (Zhang et ah, 2011).
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Figure 4.2. Solubility of CUR in POA hydrogel.
Effects of POA combinations on Cancer Cell Viability
Cell viability (MTT) assays were performed to investigate the potential 
cytotoxic effects of CUR, CPT and POA, and their various combinations on A2780, 
H I299 and DU-145 cell lines. Untreated cells served as controls. The incubation of 
cells lines was terminated at 72 hours and colorimetric determination of cell viability 
was performed. In Figure 4.3, we compared free CPT and CPT loaded POA with 
increasing concentrations of CPT. Complexes inhibited cell proliferation in all three
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cell lines in a dose-dependent manner and statistically more effectively than free CPT. 
The I C 5 0  of CPT with POA was found to be between 4.5 pM to 19.8 pM while that of 
free CPT ranged from 19.4 pM to 28.1 pM among all the cancer cell lines. This 
accounts for almost 40% reduction in the I C 5 0  value with CPT incorporated POA. The 
MTT study shows that CPT with POA were more effective in arresting cell growth as 
compared to that presented by free CPT.
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Figure 4.3. Comparison of cytotoxic effect of free CPT an<i free CUR with their POA 
hydrogel formulations on A2780, H I299 and DU-145 cell lines as assessed by the 
MTT method for 72 h. POA40 and POA80 means 40 pM and 80 pM concentration of 
POA, respectively. POA hydrogel formulation of CPT has an improved therapeutic
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effect on all cancer cell lines compared to CPT alone. On the other hand, POA raises 
cytotoxic effect of CUR especially on A2780 and DU-145 cell lines. Values are 
means (n =3) ±SD.
A2780
5  60
-  40
^  ^  0.5 3 50 0.3 5 50 0.5 5 50
§ S ë  CPT CPT+POA40 CPT+POA80
C +CUR(5nM) +CUR(5hM) +CUR(5pM)
Concentriation (jiM)
H12P9
rs 60
=  40
0.5 5 50 0.5 5 50 0.3 5 50
CPT+POA40 CPT+POA80F p  p' CFT uyi ru u Lri+ruABu
C f  +CUR(5m>I) +CUR(5hM) +CUR(5hM)
Concentriation (pM)
DU-145
^  80 -
S  60
[ C h art Area
S’ ^  0.5 5 50 0.5 5 30 0.5 5 30
CPT CPT+POA40 CPT+POA80
+CUR(5nM) +CUR(5m>D +CUR(5hM) 
Concentriation (|i\D
Figure 4.4 Cooperative cytotoxic effect of free CPT and free CUR was compared 
with CPT/POA and CUR/POA in combination on A2780, H I299 and DU-145 cell 
lines as assessed by the MTT method for 72 h. POA40 and POA80 means 40 pM and 
80 pM of POA, respectively. POA hydrogel formulation of CPT + CUR has an 
improved therapeutic effect especially on all three cancer cell lines compared to free 
CPT + CUR. Values are means (n =3) ±SD.
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MTT assays were also performed using equivalent dosages of free CUR, blank 
POA and CUR/POA for 72 hours. (Figure 4.3) Fewer viable cancer cells were seen 
for CUR/POA than the same concentration of CUR for A2780 and DU-145 cell lines. 
On the other hand, free CUR has showed slightly better dose dependent cytotoxic 
effects than CUR/POA at H I299 cell line.
Finally, to investigate synergism we tested the potential cytotoxicity o f CUR 
(5 pM) with various concentrations of free CPT or loaded in POA. (Figure 4.4) 
Notably, the IC50 values of CUR in cancer cell lines were significantly decreased by 
the addition of 5 pM CUR. I evaluated synergistic interaction according to Chou and 
Talalay multiple drug interaction analysis and combination index (Cl) values are 
presented in Table 4.1.
No synergistic effect was observed when free CPT and free CUR were 
administered alone. On the other hand, a synergistic inhibition was found between 
CPT and CUR when treated with POA on the human ovarian cancer cell line (A2780) 
and human non-small cell lung carcinoma cell line (H I299) as shown in Table 4.2. 
The effect of CPT and CUR, both alone and in combination with POA, was studied in 
growth of A2780, H I299, and DU-145 cells. The results revealed an interaction 
between CPT and CUR in several cellular processes. POA also was very promising 
for effective internalization of CPT and CUR. Development in cytotoxicity was 
correlated with enhanced intracellular and nuclear delivery of the two drugs. The 
results show that CUR enhances the cytotoxicity of CPT against three different types 
o f human cancer cells. This synergistic effect is more prominent in human ovarian 
cancer cell line (A2780) and human non-small cell lung carcinoma cell line (H I299). 
Once the synergistic effect was discovered in A2780 and H I299 cell lines.
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combination o f these drugs with POA were examined by clonogenic assay and further 
analyzed in flow cytometer in these two cell lines.
Table 4.1. The IC50 values (50% of cell growth inhibition) of CPT, CUR, CPT/POA 
and CUR/POA alone and in combination on A2780, H I299 and DU-145 cell lines.
A2780 H1299 DU-145
CPT(jiM) 25.6 28.1 19.4
CPT/POA (^M) 18.5 19.8 4.5
CUR (^M) 12.7 14.5 9.7
CUR/POA (jiM) 11.8 16.7 6.5
CPT (fiM) 2 0 .2 19.7 8 .6
+ + + +
CUR(jiM) 5.0 5.0 5.0
CPT/POA (jiM) 6 .8 7.1 1.0
+ + + +
CUR/POA (fiM) 5.0 5.0 5.0
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Table 4.2. Combination index (CI) of CPT and CUR against A2780, H1299 and DU- 
145 cell lines.
CPT (pM) + CUR (pM)
CPT/POA (pM) + CUR/POA 
(pM)
Cl
Interaction
Type
Cl
Interaction
Type
A2780 1.2 Antagonistic 0.79 Synergistic
H1299 1.0 Additive 0.66 Synergistic
DU-145 1.0 Additive 1.0 Additive
Clonogenic Assay
Clonogenic assays (colony formation assays) of cells were performed to 
investigate the long-term anti-cancer efficacy of parent drugs and their combination 
with POA. (Figure 4.5) Cell lines selected for the colony formation assay included 
A2780, H I299. CPT/POA combination showed increased therapeutic effect compared 
to free CPT on A2780 and H1299 cell lines. Results from the colony formation assay 
indicate that a significant improvement in the therapeutic efficacy of CUR/POA 
combined in both cell lines compared to free CUR. This enhancement is more 
prominent in A2780 cell line.
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Figure 4.5. (A) Representative images of colony forming assays free CPT and CPT in 
POA hydrogel. (C) Representative images of colony forming assays CUR and CUR in 
POA hydrogel. Cells (500) were seeded in culture dishes and after 24 h treated with 
the indicated amounts of amounts of anticancer agents. Cells were allowed to grow 
for 11 days. (B), (D) Colony densities were expressed as a percent of the control cells 
at A2780 and H I299 cell lines. The results show the mean± SE values, (p < 0.05, 
compared to the same CPT or CUR dose).
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Flow Cytometry Analysis
Flow cytometry analyses of the apoptosis induced by CUR and CPT were 
carried out by performing PE Annexin V and 7-AAD staining on A2780, H I299 and 
DU-145 cell lines. PE Annexin V measures the loss o f phospholipid asymmetry and 
the accumulation of phosphatidylserine to the outer leaflet of the plasma membrane 
taking place early during apoptosis and it is used to quantitatively determine the 
percentage of cells within a population that are actively undergoing apoptosis. (Figure 
4.6) 7-AAD is a standard flow cytometric viability probe and is used to distinguish 
viable from nonviable cells. (Figure 4.7) Viable cells with intact membranes exclude 
7-AAD, whereas the membranes of dead and damaged cells are permeable to 7-AAD. 
Cells that stain positive for PE Annexin V show apoptosis and cells that stain positive 
for 7-AAD are already dead.
Quantitative apoptotic and necrotic activity analysis were achieved by flow 
cytometry in CPT and CUR treated cells. Analysis shows that both drugs induce 
apoptosis on all cancer cell lines studied. Combination therapy with POA hydrogel 
suppressed the growth of all cell types even at lower doses and resulted in significant 
induction of both apoptosis and necrosis. The synergistic effect on cell apoptosis were 
even more prominent when both drugs administered with POA combined in A2780 
and H I299 cell lines. Flow cytometry analysis revealed that POA in combination with 
CPT and CUR highly effective in inducing the cellular apoptosis and cell death. These 
results correlate well with the cell viability and colony formation data to confirm that 
POA plays a key role for delivering the hydrophobic CUR.
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Figure 4.6. POA hydrogel mostly increases the number of apoptotie eells. Human 
ovarian eancer cell line A2780 (A) and human nonsmall cell lung carcinoma cell line 
H I299 (B) were treated with CPT and CUR alone or in eombination which are
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formulated in solution and POA formulation for 48 h. Apoptotic cells were measured 
with PE Annexin V staining by using flow cytometry.
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Figure 4.7. Cell death was determined with 7-AAD staining. A2780 and H1299 
eaneer cell lines were treated with CPT and CUR alone or in combination which are 
formulated in solution and POA formulation for 48 h.
4.5. D iscussion
The study of poloxamer block copolymers in the field o f drug delivery for 
chemotherapy continues to grow thanks to their unique properties such as thermo­
sensitive sol-gel properties, ability to form micelles, and sensitize cancer cells (Exner 
et ah, 2005; Guo et al., 2007; Wei et al., 2010). In the present study, a novel nano- 
earrier for the eombination delivery of multiple drugs has been developed by using 
thermo-sensitive polymeric micelles as a facile platform. I have synthesized the
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polymeric micelle, which is oleic acid coupled Poloxamer block copolymer, through 
one pot estérification without any solvent or catalyst. Solubility studies showed that 
oleic acid coupled poloxamer increases solubility of hydrophobic chemotherapeutics 
like CUR. It was proposed that CUR loading in the Poloxamer micelles is supposed to 
arise from the partitioning of the hydrophobic drug within the core o f the micelles 
formed by self-assembly of the tri-block copolymers in aqueous solution (Sahu et ah, 
2011). CUR inhibits the cancer cell growth by multiple mechanisms including 
nuclear factor-kappa B (NF-kB), transcription factor activator protein-1 (AP-1), 
mitogen activated protein kinase (MARK), tumor protein 53 (p53), nuclear p-catenin 
signalling, and AKT signalling pathways (Gupta et ah, 2013). CUR has proven to 
suppress the expression of cancer associated growth factor such as epidermal growth 
receptor and estrogen receptors (Yallapu et ah, 2012b). It was also shown that CUR 
efficiently sensitizes tumor cells to first line chemotherapies and radiation (Ganta and 
Amiji, 2009; Johnson and Mukhtar, 2007). CPT is widely used in treatment different 
types o f cancers, including testis, ovary, bladder, head and neck, and lung cancer (Ali 
et ah, 2013). It is a DNA crosslinking agent that covalently binds DNA and blocks 
DNA replication to trigger apoptosis (Florea and Biisselberg, 2011). I demonstrated 
that both CUR and CPT are potent enough to inhibit cell proliferation in all three cell 
lines. (Figure 4.3) Cancer cells gain drug resistance like microorganisms get antibiotic 
resistance by various mechanisms including decreased uptake of water-soluble drugs, 
such as folate antagonists, nucleoside analogues and CPT, which all require 
transporters to enter cells, and by various changes in cells that affect the ability of 
cytotoxic drugs to kill cells, such as alterations in cell cycle (Duarte et al., 2010) 
Efficacy of CPT is also diminished by drug resistance in the advanced stages of the 
cancer (Florea and Biisselberg, 2011). It was reported that poloxamer sensitize
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multidrug resistant cells to chemotherapy and enhance the cytotoxic activity of a drug 
by two to three orders of magnitude (Amiji et ah, 2002). It was also shown that fatty 
acids increases the cytotoxic activity of some anti-cancer drugs (BartoH et ah, 2000). 
The synergistic effect of combining both CUR and CPT in oleic acid coupled 
poloxamer was assessed. (Figure 4.4) Significant decrease in I C 5 0  of the POA with 
CPT and CUR as compared to free CPT and free CUR, respectively, was observed. 
Also the synergistic interaction in growth of A2780, H1299, and DU-145 cells was 
evaluated according to Chou and Talalay multiple drug interaction analysis and 
combination index (Cl) in Table 4.2. Studying the efficacy of both CPT and CUR 
alone and in combination with POA has revealed the synergistic effect on A2780 and 
H I299 cell lines. The results demonstrated the enhanced effect o f CPT with 5 pM of 
CUR. POA hydrogel in the presence of CPT improved the cytotoxicity o f CPT both 
alone and combination with CUR.
Colony formation results also confirmed that therapeutic efficacy of CUR and 
CPT was improved when treated with POA. A2780 and H I299 cell lines, the only cell 
lines on which CPT, CUR and POA showed synergistic effects, were selected for the 
colony formation assay.
Quantitative apoptotic and necrotic activity analyses were achieved by flow 
cytometry in CUR and CPT treated cells. Analyses showed that both drugs induce 
apoptosis on A2780 and H1299 cancer cell lines. (Figure 4.6) Combination therapy 
with POA suppressed the growth of each cell type even at lower doses and resulted in 
a significant induction of both apoptosis and necrosis. The apoptotic effects were even 
more prominent when the drugs administered with oleic acid-coupled poloxamer in 
human ovarian cancer cell line (A2780). In addition, flow cytometry analysis revealed 
that POA makes CUR and CPT highly effective in inducing the cellular apoptosis and
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cell death. These results correlate well with the cell viability and colony formation 
assays to confirm that oleic acid coupled poloxamer play an important role for 
delivering both hydrophobic and hydrophilic drugs such as CUR and CPT into the 
tumor cells.
Various studies have demonstrated the effect of oleic acid, a lipid penetration 
enhancer, in transdermal delivery of drugs (Idrees et al., 2011; Moreira et al., 2010a, 
2010b). Previously, poloxamer block copolymers were used for delivering various 
drugs including chemotherapeutics (Morishita et al., 2001; Nie et al., 2011; Seo et al., 
2008). Coupling these nano-carriers with oleic acid not only increases the stability of 
the polymeric micelles but also allow transdermal delivery of chemotherapeutics so 
that it could avoid the side effects associated with systemic delivery. The effect 
transdermal delivery of chemotherapeutics in combination with OA-coupled 
poloxamers needs to be further studied.
In conclusion, both CUR and CPT were successfully loaded into POA and 
delivered into human cancer cells to induce apoptosis. Our results consistently show 
that CUR and CPT in POA are more cytotoxic to cancer cells than free CUR and free 
CPT. Furthermore, we demonstrated a highly synergistic interaction between CUR 
and CPT when combined with OA-coupled Poloxamer on human ovarian cancer cell 
line (A2780) and human non-small cell lung carcinoma cell line (H I299). The oleic 
acid coupled Poloxamer enhanced cytotoxic activity of CUR and CPT in combination 
may be attributed to synergistic behaviour and augmented intracellular drug delivery 
efficiency of multiple drugs. Both hydrophobic and hydrophilic drugs can show 
increased therapeutic effect when administered with oleic acid coupled poloxamer.
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Chapter 5
Conclusions and Future Directions
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The use of cytotoxic chemotherapic agents is the most common method for the 
treatment of metastatic cancers. Poor water solubility and low efficiency of 
chemotherapic agents are among the major hurdles of effective chemotherapy 
treatments. In this work, three different novel drug formulations designed to improve 
the chemotherapeutic activity of paclitaxel, curcumin and cisplatin.
Paclltaxe
L-Glutamic 
Acid
Cyclodextrin 
Paclitaxel/CD-Glu complex
Figure 5.1. Representation of complexation of paclitaxel with L-glutamic acid 
derivative of P-cyclodextrin (Chapter 2).
Initially, novel L-glutamic acid derivative of P-cyclodextrin (CD-Glu) was 
synthesized by a one pot condensation reaction of the triazine derivative of P~ 
cyclodextrin and L-Glutamic acid monosodium salt hydrate under alkaline conditions. 
The encapsulation behaviour of paclitaxel by CD-Glu was investigated in order to 
enhance the aqueous solubility and therapeutic activity of paclitaxel. The 
encapsulated form of paclitaxel led to a remarkable increase in its water-solubility
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compared to the non-encapsulated form. In addition, our results consistently 
demonstrate that encapsulated paclitaxel is more cytotoxic to cancer cells than free 
paclitaxel particularly for ovarian, lung and prostate cancer cells.
Curcumin
Triazine
Paclitaxel
PCDT
monomer
Triazine
PCDT
monomer
Figure 5.2. Representation of complexation of curcumin and paclitaxel with Poly(P- 
cyclodextrin-triazine) (PCDT) monomer (Chapter 3).
Secondly, Poly(P-cyclodextrin-triazine) (PCDT) was prepared by 
polycondensation of the p-cyclodextrin-triazine derivative with the molecular mass of 
25.7 kg m ol'\ Hydrophobic anticancer drugs, curcumin and paclitaxel, were 
successfully encapsulated into PCDT and delivered into human cancer cells to induce 
apoptosis. Moreover, our results consistently demonstrate that encapsulated curcumin 
is more cytotoxic to cancer cells than free curcumin. On the other hand, encapsulation 
in PCDT did not change cytotoxicity of paclitaxel significantly, which urges further 
studies on different encapsulation approaches. Curcumin alone increases free 
paclitaxel’s cytotoxicity synergistically only for H I299 cell line. Further, we
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demonstrated a highly synergistic interaction between curcumin and paclitaxel 
complexed with PCDT in two human ovarian carcinoma cells and a human nonsmall 
cell lung carcinoma cell. This synergistic therapeutic method with PCDT 
encapsulation offers considerable potential in the clinical trials for ovarian and lung
cancers.
Cisplatin Cnrcumin
> c ;
CH3 O O CH3
O CH3
,C-0-[-CH2CH20^ CH sCH O ^ CH2 CH2O]— H
Figure 5.3. Structures of cisplatin, curcumin and oleic acid coupled poloxamer (POA) 
(Chapter 4).
In addition to cyclodextrins, hydrogels are also remarkable candidates in drug 
delivery applications, by reason of their notable resemblance to natural living soft 
tissues, applicability for both hydrophobic and hydrophilic agents and their 
biocompatibility. Thus, oleic acid coupled poloxamer (POA) was synthesized through 
ester linkage between the carboxyl group of oleic acid and the hydroxyl group of 
poloxamer without any solvent. Both curcumin and cisplatin were successfully loaded 
into novel oleic acid coupled poloxamer and delivered into human cancer cells to 
induce apoptosis. Our results consistently show that curcumin and cisplatin in POA 
are more cytotoxic to cancer cells than free curcumin and free cisplatin and analysis 
of apoptosis by Annexin V revealed that POA increases cisplatin and curcumin
140
induced apoptosis in A2780 and H1299 cell lines. Furthermore, we demonstrated a 
highly synergistic interaction between curcumin and cisplatin when combined with 
OA-coupled poloxamer on human ovarian cancer cell line (A2780) and human non­
small cell lung carcinoma cell line (H I299). The oleic acid coupled poloxamer 
enhanced cytotoxic activity of curcumin and cisplatin in combination may be 
attributed to synergistic behaviour and augmented intracellular drug delivery 
efficiency of multiple drugs. Both hydrophobic and hydrophilic drugs can show 
increased therapeutic effect when administered with oleic acid coupled poloxamer.
Table 5.1. Cl values for A2780, SKOV-3, H1299, DU-145 and MCF-7 cell lines.
Paclitaxel
+
Curcumin
Paclitaxel/PCDT
+
Curcumin/PCDT
Cisplatin
+
Curcumin
Cisplatin/POA
4-
Curcumin/POA
A2780 1.0 0.70 1.2 0.79
SKOV-3 1.0 0.78 N/A N/A
H1299 0.83 0.69 1.0 0.66
DU-145 1.3 1.3 1.0 1.0
MCF-7 1.0 1.0 N/A N/A
Table 5.1. displays the comparison of Cl values for four drug formulations 
treated on A2780, SKOV-3, H1299, DU-145 and MCF-7 cancer cell lines. 
Paclitaxel/PCDT and curcumin/PCDT in combination is the most efficient one among 
the formulations studied on A2780 and SKOV-3 ovarian cancer cell lines. On the 
other hand, combination of cisplatin/POA and curcumin/POA is the best approach for
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H1299 cancer cell line. In the case of DU-145 and MCF-7 cell lines, all formulations 
showed either additive or antagonistic effect. Based on these results, the enhanced 
solubility, stability and bioactivity o f paclitaxel, curcumin and cisplatin may be of 
particular importance in future therapeutic applications o f these anticancer agents and 
may provide basis for the treatment of various cancer types. The findings display the 
possible use of curcumin in combination particularly with paclitaxel and cisplatin in 
cyclodextrin polymer and POA hydrogel formulations, respectively. In addition to 
cisplatin and paclitaxel, some other anticancer agents such as camptothecin, 5- 
fiuorouracil, carboplatin, oxaliplatin etc. can be considered with these novel 
formulations as a part of the future work.
Although, these formulations are cytotoxic against cancer cell lines, their 
effects on normal cells are not known. Thus, toxicity and bioavailability o f the novel 
formulations has to be investigated in pre-clinical animal models. Besides, it would be 
beneficial to consider the response o f the cancer cells after the treatment with the 
formulations. A method can be designed that firstly cells are treated with anticancer 
drug formulations, then incubated for a few days without any drug administration and 
again treated with formulations. This cell response study could give information about 
whether any resistance of the cancer cells occurs against the formulations.
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Abbreviations
AP-1 transcription factor activator protein-1
^H-NMR nuclear magnetic resonance with respect to hydrogen-1
7-AAD 7-amino-actinomycin
A2780 human ovarian cancer cell line
AA acrylic acid
Akt protein kinase B
AP-1 activator protein-1
CD cyclodextrin
CDCI3 deuterated chloroform
CD-Glu L-glutamic acid derivative of b-cyclodextrin
CD-TRl p-cyclodextrin triazine
Cls combination indices
CO2 carbon dioxide
CPT cisplatin
Cremophore EL polyoxyethylated castor oil derivative
Cur curcumin
DMSG dimethyl sulfoxide
DNA deoxyribonucleic acid
DU-145 human prostate carcinoma cell line
EDTA ethylenediaminetetraacetic acid
EG Ethylene glycol
EGDMA ethylene glycol dimethacrylate
EG ethylene oxide
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FDA American Food and Drug Administration
FGF fibroblast growth factor
FT-IR fourier transform infrared spectroscopy
GPC gel permeation chromatography
H1299 human nonsmall cell lung carcinoma cell line
HDEEMA hydroxydiethoxyethylmethacrylate
HEEMA hydroxyethoxyethylmethacrylate
HEMA hydroxyethyl methacrylate
HPLC high-performance liquid chromatography
HPMA N-(2-hydroxypropyl)methacrylamide
lARC International Agency for Research on Cancer
IC50 the concentration of drug that produces 50% of cell growth inhibition
IKKp IkB kinase P
KBr potassium bromide
Kc stability constant
MALDI-TOF-MS matrix assisted laser desorption/ionisation mass spectrometry
MAPK mitogen activated protein kinase
MCF-7 human mammary adenocarcinoma cell line
MDEEMA methoxydiethoxyethylmethacrylate
MEEMA methoxyethoxyethylmethacrylate
MEMA methoxyethyl methacrylate
MMPs matrix metalloproteinases
MTT 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2//-tetrazolium bromide
NCI National Cancer Institute
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NF-kB
NIPAAm
Nrf2
NVP
OA
P
p53
Pax
PBS
PCDT
PE Annexin V
PEGA
PEGDA
PEGDMA
PEGMA
PEG
PG
PGA
PPG
S.E.M.
SD
SKGV-3
VAc
VEGF
nuclear factor-kappa B 
N-isopropyl AAm
nuclear factor (erythroid-derived 2)-like 2
N-vinyl-2-pyrrolidone
oleic acid
polymer backbone
tumor protein 53
paclitaxel
phosphate buffered saline
poly(b-cyclodextrin triazine)
phosphatidylethanolamine Annexin V
PEG acrylate
PEG diacrylate
PEG dimethacrylate
PEG methacrylate
poly(ethylene oxide)
propylene oxide
oleic acid coupled poloxamer
poly(propylene oxide)
standard error of the mean
standard deviation
human ovarian cancer cell line
vinyl acetate
vascular endothelial growth factor
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Definitions
Apoptosis: The process of programmed cell death (PCD) that may occur 
in multicellular organisms.
Bioavailability (BA): A subcategory of absorption and is the fraction of an 
administered dose o f unchanged drug that reaches the systemic circulation, one o f the 
principal pharmacokinetic properties of drugs.
Chemotherapy: The treatment o f cancer with one or
more cytotoxic antineoplastic drugs ("chemotherapeutic agents") as part o f a 
standardized regimen.
Hepatotoxicity: Chemical-driven liver damage. The liver plays a central role in 
transforming and clearing chemicals and is susceptible to the toxicity from these 
agents.
Hypersensitivity: Undesirable reactions produced by the normal immune system, 
including allergies andautoimmunity.
IC50 (The half maximal inhibitory concentration): A measure o f the effectiveness 
o f a compound in inhibiting biological or biochemical function. This quantitative 
measure indicates how much of a particular drug or other substance (inhibitor) is 
needed to inhibit a given biological process.
Microtubules: A component o f the cytoskeleton, found throughout the cytoplasm. 
They are found in eukaryotic cells and are formed by the polymerization of a dimer of 
two globular proteins, alpha and beta tubulin.
Necrosis: A form of traumatic cell death that results from acute cellular injury, 
apoptosis generally confers advantages during an organism's life cycle.
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Neurotoxicity: occurs when the exposure to natural or artificial toxic substances, 
which are called neurotoxins, alters the normal activity of the nervous system in such 
a way as to cause damage to nervous tissue.
Terminal half-life: The time it takes for a substance (for example
a metabolite, drug, signalling molecule, radioactive nuclide, or other substance) to 
lose half o f its pharmacologic, physiologic, or radiologic activity, as per 
the MeSH definition.
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